2012/13 - gallipoli – enhancing health through the ... · 2012. terry’s phd focused on liver...

2012/13AnnuAl RepoRt

Gallipoli M

edical Research Foundation An

nu

al Rep

ort 2012 – 2013

2

Contents

3 Highlights

4 Message from the Chairman

5 Message from the Ceo

7 Message from the Director of Research

8 GMRF profile

9 Research Activities

18 Board of Directors

23 Committees

24 Acknowledgements

26 Financial Statements

50 How you can help

Gallipoli M


nu

al Rep

ort 2012 – 2013

3

Highlights 2012–2013• TheGMRFFlagshipprogramintoPostTraumaticStressDisorder(PTSD)wasinitiatedinthelast12months.Fromthesparkofanideatothefulldevelopmentofastudyprotocolithasbeenawhirlwindyear.GMRFreceivedanenormousamountofhelpfromtheGPHdoctorsandadvisorsforwhichweareverygrateful.

• RSLQLDjoinedGMRFinpartnershiptohelpfundtheflagshipVietnamVeteranPTSDprojectwithadonationof$1millionplusanadditional$750Koverthecoming3years.

• ProfessorDarrellCrawford,DirectorofResearchatGMRFwasnamedtheactingHeadofTheUniversityofQueenslandSchoolofMedicineandelectedPresidentofTheAsianPacificAssociationfortheStudyofTheLiver.

• ThefederalinfrastructuregrantwasfullyacquittedresultinginstateoftheartfacilitiesforthescientistsandclinicalresearchersatGMRF.

• TheCentreforImmuneandTargetedTherapywasawardedagrantfromComCarefortheconductofaclinicaltrialinmesotheliomacombiningimmunotherapywithstandardtherapytofightthisdisease.

• TheGMRFclinicaltrialsunitandDrJeffGohrecruitedthelargestnumberofpatientsinaninternationalclinicaltrialinovariancancerinvestigatinganewcancervaccinecalledCVac.

• GMRFcontinuestoleadthewaywiththesupportofaHepatitisEducationNursefortheGPHbulkbillliverclinictosupportthosesufferingfromHepatitis.TheclinicaltrialsunitalsoprovideaccesstothelatestHepCtreatmentsthroughourclinicaltrialsunit.

• DiscoveryPartnerMarjorieTrundleisoneofthefirsttopledge$30,000over3yearstothecancerresearchworkofDrAndrewNicolunderthisnewGMRFsupportersprogramcalledtheDiscoveryPartnerProgram.

• GMRFcontinuestoinvestinthebestandbrightestpeople.DrTerranceTanreceivedhisPHDinDecember2012.Terry’sPHDfocusedonliverscarring,ironoverloadandnon-alcoholicfattyliverdisease.Terryhaspublishednumerouspapersandpresentedatfournationalandinternationalconferencesonhiswork.GMRFcontinuestosupportanadditionalfourPHDscholarships.

• JohnandWendyThorsencontinuetodemonstratetheircommitmenttotheFoundationbyjoiningusinourquesttoinvestinthebestandbrightest.TheThorsenFamilyFoundationhasprovidedfundstosupporttwofullPHDscholarships.TheJohn and Wendy thorsen pHD ScholarshipswillbeawardedtoexceptionalcandidatesthatmeetselectioncriteriaestablishedbytheGMRFResearchandGovernanceSubcommittee.

• TheLiverResearchUnithavedemonstratedthatalongwithdietarychanges,curcuminandvitaminEmayplayaroleinpreventingliverdamageorassistrecoveryfrominflammationandfattyliverdisease.

• DrRachelThomsonandherteamcontinuetheworkinNontuberculousMycobacterium(NTM)discoveringthattherearestrainswhicharemorelikelytocausediseasethanothers.BetterunderstandingofthesestrainscouldbethekeyinfightingNTM.

• AclinicaltrialinmetastaticmelanomaledbyDrAndrewNicolwillexplorewaystopotentiallyenhancethebenefitsofCITT’spersonalisedvaccinetherapy,byadministeringitafterchemotherapy.

• GreenbankRSLWomen’sAuxiliaryinvested$10,000intoGMRFresearch.

• TheCentreforImmuneandTargetedTherapyhasestablishedanexcitingcollaborationwithDrTetsuyaNakatsurafromthenationalcancerhospitalinJapaninthehopeofdevelopingtechniquesthatcanbeusedineverydayclinicalpracticetodetectrecurrentmelanomaataveryearlystage.

• GMRFcontinuestobenefitfromthewonderfulcommunityfundraisingeffortsofGill’sOldBastardsandAlmaWilliamsandFriends.

• GMRFInnovationGrantsagreatsuccesscontinuingin2013forthesecondyear.

• BobandBernadetteNeygenerouslydonated$10,000overasixmonthperiodtosupporttheworkoftheFoundation.

• GMRFprovidesvitalfundstowardsthedaVincirobotatGPH.TherobotisrevolutionizingtreatmentforprostatecancerandopensthewaysforGMRFtocontributetoexcitingresearchopportunitiesinprostatecancer.

Gallipoli M


nu

al Rep

ort 2012 – 2013

4

Message from the Chairman Tom RyanGallipoliMedicalResearchFoundationisaconduitthroughwhichthebeliefandhopeofoursupporterscanbeturnedintomedicaladvancements.Itistheirsupportwhichturnsthewheelsofdiscoveryforward,complementedbythededicatedinvestigationofourdoctorsandscientists.

AllwhoserveontheGMRFBoardarepassionateaboutdirectingthissupporttothemostinnovativeresearchpossible.Researchthathasthecapacitytoimprovethequalityoflifeforsuffererstoday,aswellasgame-changingresearchthatwillonedayalterthefutureofmedicine.

Withthecompletionoftheinfrastructuregrant,theGMRFfacilitiesarenowsecondtonone.Afacilitytrulyintegratedintothiswonderfulteachinghospital.TheGMRFInnovationGrantwinnersfor2012demonstratethewealthoftalentandresearchquestionstobeansweredwithinthehospitalbynursingandalliedhealthprofessions.GMRFisproudtosupporttheirenquiringmindsinthepursuitofimprovedpatientoutcomes.

InMay2013welaunchedtheCyrilGilbertTestimonialFundResearchGrants,availabletocancerresearchersandphysiciansatGreenslopesPrivateHospital.Stilltoday,fartoomanystoriesareprematurelycutshortduetothemanyformsofunforgivingcancer.SupportersofGMRFhaveallowedanotherseriouspushbehindthisresearchthatexploreswaystooutsmartandeventuallymastercancer.

ThePTSDProjectisthelatestinitiativeoftheFoundation,whichwaslaunchedearlierthisyear.WearesoappreciativefortheoutpouringofsupportwereceivedfortheGMRFPTSDresearchproject.AussieDiggersaredeeplyrespectedandhonouredinAustralianculture,andfartoomanyofoursoldierssufferasaresultoftheirservice.ThecommitmentofRSLQLDandtheGMRFsupportershasmeantwecanexplorenewwaystobringthesesoldiershomefromthewartheyarefightinginside.

Thejourneyfromscientificinsightthroughtonewtreatmentscanbealongone,requiringcourageandcommitment.Alongthewaythougharefantasticdevelopments,whichoursupporterscontinuetomakepossible.

Thereissomuchmoretodo,andsomuchmorethatispossible.Thelifesavingbreakthroughsoftomorrowaresecuredbytheactionsofoursupporterstoday.OnbehalfoftheGMRFBoard,thankyouformakingsomuchpossible–wearetrulyhonouredtobeworkingalongsideyou.

tom Ryan – Chairman

Research that has the capacity to improve the quality of life for sufferers today, as well as game-changing research that will one day alter the future of medicine.

Gallipoli M


nu

al Rep

ort 2012 – 2013

5

Message from the Ceo Miriam DwyerAsignificanthealthissueforveteransovertheyearshasbeenthatofPost-TraumaticStressDisorder(PTSD).CliniciansandscientistsworkingatGPHrecognisethatPTSDisnotjustanillnessofthemind;thelongtermhealthconsequenceofPTSDgoesmuchfarther.

ResearchersattheGallipoliMedicalResearchFoundationarenowinthefinalstagesofpreparationforthePTSDstudywhichwillstudyveteranswithandwithoutPTSDtobetterunderstandthelongtermphysicalimpactonthosesufferingfromPTSDandendeavourtobetterunderstandthegeneticsofthedisorder.InpartnershipwithRSLQLD,whohasprovidedgenerousfundstohelpsupportthisresearch,thecliniciansatGPHandtheGMRFresearcherswillcollaboratewithUQandQUTwiththelongtermaimofprovidingvaluabledata,toinformthefutureclinicalcareofPTSDpatientsandtheirfamilies.ThisisthefirststudyofitskindintheworldandwearehonouredtobeinapositiontobeabletofacilitatethisresearchhereatGreenslopes.

AnothersignificantdevelopmenthereatGMRFhasbeentheexpansionofourclinicaltrialsunit.Theverylatestclinicaltrialsinoncology,haematologyandhepatitiscaremanagedhereatGPHwiththesupportofthededicatedGMRFclinicaltrialcoordinators.AccesstothelatestcancerdrugsneedstobeanoptionforpatientsandhereattheCyrilGilbertCancerCentre,investigatorsareleadingthewaywithofferingclinicaltrialopportunitiestotheirpatients.

Withthehelpofourgenerouscorporate,communityandindividualsupporters,GMRFisfacilitatingmoremedicalresearcheveryday.Weprovide$30,000eachyeartotheGPHNursingandAlliedHealthstaffbywayoftheGMRFInnovationGrantsandthisyearwelaunchedtheCyrilGilbertTestimonialFundGrantsincancertreatmentandcarewithatotalpoolof$150,000.Wefundresearchthatisclinicallyrelevanttopatientsandtheirclinicians,thebenefitsofwhichwehopewillbesharedbythewiderhealthcarecommunity.

Icannotthankoursupportersenoughfortheirgeneroussupport,withoutwhichthisimportantworkwouldnotbepossible.SpecialmentiongoestoRSLQLDwhohascommitted$1.75MilliontothePTSDProjectandtoKedronWavellRSLClubandSubBranchwhorecentlymadearecommitmentof$50,000overthecoming5years.ThanksalsotoJohnandWendyThorsenfortheircontinuedsupportoftheFoundationbyprovidingtwofullPHDscholarships.

IalsowanttoacknowledgethecommitmentoftheFoundation’slongtermsupporters;GreenslopesPrivateHospital,theDiggersDozen,SullivanandNicolaidesPathology,UniversityofQueenslandandthemanyindividualswhoensurethisimportantworkcontinues.

Researchers at the Gallipoli Medical Research Foundation are now in the final stages of preparation for the PTSD study which will study veterans with and without PTSD to better understand the long term physical impact on those suffering from PTSD and endeavour to better understand the genetics of the disorder.

Gallipoli M


nu

al Rep

ort 2012 – 2013

6

Message from the CEO continued

We fund research that is clinically relevant to patients and their clinicians, the benefits of which we hope will be shared by the wider healthcare community.

MythanksalsogoestothemembersoftheGMRFboardandtheadvisorycommitteesfortheirsupportinthepast12months,especiallytoTomRyan,whoasChairoftheboard,hasbeenbesidemeallthewaythisyearprovidingsoundadviceandsupportforwhichIamverygrateful.Last,butbynomeansleast,IwanttothanktheamazingteamthatIworkwithhereatGMRF.EachindividualcontributesintheirownwaytothesuccessoftheresearchbreakthroughsandIamveryproudtoleadsuchadedicatedandhardworkingteam.

IencourageyoutofindoutmoreabouttheFoundationbyvisitingthewebsitewww.gallipoliresearch.com.auorbycontactingourstaffforatourofthefacilitiesorconsiderjoiningourmailinglisttoreceiveournewsletterTribute.Feelfreetocall0733947284oremailenquiries.gmrf@ramsayhealth.com.au

Miriam Dwyer – Cheif Executive Officer

Gallipoli M


nu

al Rep

ort 2012 – 2013

7

Message from the Director of Research Prof Darrell Crawford Theprogressionofmedicineneedsclinicianstobeattheforefrontofresearch.Doctorsworkingonthefrontlineofmedicinearebetterabletoseewhereresearchcandirectlyhelppatients,andinsightsfoundintheGMRFlaboratoriesarefrequentlytranslatedintohelpingpatients.ComplementingthisistheGMRFclinicaltrialsunit,whichmanagesupto30clinicaltrialsatatime.Thesetrialsgivedoctorsthechancetoofferthenextgenerationofpotentiallylifesavingmedicinetotheirpatients.SinceredevelopingGMRF’sfacilities,ourclinicaltrialsteamhasmorethandoubleditscapacitytohelpthosewhoareseriouslyill.

Largerandmoresophisticatedlaboratorieshavealsohelpedusattractnewresearchers.Expandingourcollaborationswithotheracademicandresearchgroupshasallowedustotacklesomeoftheworstdiseasesofourtime.AnexampleofthisisHCCprimarylivercancer,whichhasthefastestgrowingincidencerateofallcancersinAustralia,whichGMRFhasnowcreatedadedicatedunittoinvestigate,ledbyaninternationallyexperiencedscientist.ThisunitwillopeninNovember2013.

OurresearchfacilitieshavealsoallowedustosupportandencourageresearchatalllevelsatGPH.Researchinnovationgrantshaveprovidedawayfornursesandalliedhealthprofessionalstoexploretheirpracticalideastoimprovepatientcare.GMRF’sadvancedmedicaltraineegrantshelpearlycareerphysiciansgetinvolvedwithresearch,potentiallylightingalifelonginterestinmedicalresearch.

Securingfuturebreakthroughsrequirescultivatingthebrightyoungmindsoftoday.GMRFsupportsfiveupandcomingresearcherstomaketheirmarkonaninnovativeGMRFresearchproject,throughGMRFfundedPHDscholarships.

GreenslopesPrivateHospitalisnowoneoftheonlyprivatehospitalsinAustraliatohaveworldclassresearchlaboratories,leveragingtheuntappedwealthofexpertiseintheprivatehospitalenvironmentformedicalresearch.Studieshaveshownthathospitalswithanacademicandresearchcomponentoftenhavebetteroutcomesforpatients.AtGMRFandGPHthesestudiesaredemonstratedeveryday.

prof Darrell Crawford – Director of Research

Greenslopes Private Hospital is now one of the only private hospitals in Australia to have world class research laboratories, leveraging the untapped wealth of expertise in the private hospital environment for medical research.

Gallipoli M


nu

al Rep

ort 2012 – 2013

8

GMRF Profileour VisionWebelievethatthediseaseswhichindiscriminately

affectboththeyoungandold,canandmustbe

conqueredinourlifetimethroughmedicalresearch.

Inourvitalworkoffacilitatingdiscoveries,weremember

andtakeinspirationfromthedisciplineanddedication

exemplifiedbyourveterans.

GMRF Foundation Mission:GMRF’ssupportersholdadeepbeliefthatmedical

researchcanchangelives.Weaimtoturntheirbelief

intobreakthroughsbyraisingandinvestingfundsinto

theinnovativescientificdiscoveriesoftomorrow.

Weensurethatourscientistshavethetime,spaceand

resourcesrequiredtofindnewwaystosavelives.

GMRF Research Mission:GMRFisdriventoimprovehumanhealthbyidentifyingandexploringthegapsincurrentscientificknowledge.Beyondtheboundariesoftoday’streatments,wesearchforanswerstothemostchallengingmedicalquestions.Thedepthandqualityofthisresearchisaresultofrelentlesslyfocussingonourstrengthsandspecialisations.Webringtogetherthebestideasandindividualsinpursuinggamechangingdiscoveries.

our Strategy:1. Providetheinfrastructure,governanceandresourcestosupportexistingandfutureresearchendeavours.

2. FacilitateandsupportacultureofmedicalresearchwithintheGreenslopesPrivateHospitalthroughcompetitivescholarshipsandgrants.

3. Communicateeffectively,therebyincreasingcommunityandcorporatesupportfortheFoundationanditsresearch.

4. Consistentlydeliverexceptionalclinicalresearchactivitytoourpatientsandsponsors.

5. Expansionwithinourspecialisationsandareasofexpertisetoincludeadditionalresearchthemes.

TheGallipoliMedicalResearchFoundationissupportedbyaBoardofDirectorsandResearchCommitteemadeupofhighlyqualifiedandesteemedindividuals.TheNationalHealth&MedicalResearchCouncil(NH&MRC)hasapprovedtheGallipoliMedicalResearchFoundationasanApprovedResearchInstitute(ARI).TheFoundationisendorsedbytheAustralianTaxationOffice(ATO)asaDeductibleGiftRecipient(DGR).Accordingly,gifts(notbeingtestamentarygifts)ofthevalueof$2andabovearetaxdeductible.

Gallipoli M


nu

al Rep

ort 2012 – 2013

9

Research Activities Centre for Immune and Targeted Therapy – led by Associate Professor Andrew Nicol TheCentreforImmuneandTargetedTherapy(CITT)isattheleadingedgeoffindingwaystoharnesstheimmunesystemtofightcancer.Researchersareexploringwaystocombineimmunotherapywithstandardcancertreatments,includingchemotherapy,tomaximisethepotentialanticanceractivitywithoutincreasingthetoxicityofthetreatment.CITTiscurrentlyfocussingourresearcheffortsonmelanoma,thebonemarrowcancermyelomaandmesothelioma.

Sinceourinception,amajorgoaloftheCITTwastobuildastrongresearchteaminvolvingproductivecollaborationsbetweencliniciansandnon-clinicalscientists.Suchpartnershipsareknowntobehighlyproductiveinmedicalresearchandallowmaximumutilisationoftherespectiveability,expertiseandexperienceofcliniciansandscientists,particularlyinclinically-orientedresearch.CITTplanstoappointaSeniorScientisttoleadthescientificaspectsofourresearch,enhancecollaborationsbetweencliniciansandscientistsatGreenslopesandenhancethecollaborationsoftheCITTwithotherleadingresearchteams.

Amajorachievementoftheprevious12monthshasbeenthedesignanddevelopmentofthreeprotocolsforinvestigator-initiatedclinicaltrialsinmelanoma,myelomaandmesothelioma.EthicsapprovalshavebeengrantedthroughboththeGreenslopesPrivateHospitalandUniversityofQueenslandHumanResearchEthicsCommittees.

Metastatic MelanomaStageIVmetastaticmelanomaisaconditionthatiscurrentlyincurablebutwhichhasbeenshowntorespondtoavarietyofimmunestimulatorymanoeuvres.InadditiontocontinuingtrialsofimmunetherapybasedonCITT’sexpertiseinthisfield,weareincreasingourcollaborationswithmajorpharmaceuticalcompaniesdevelopingdrugsformelanomabasedonrecentunderstandingofwhatdrivesthecancerousprocessinmelanoma.WithIpilimumabnowavailablethroughthePBS,recruitmenthasrecommencedCITT’strialinvestigatingstandardchemotherapy(Fotemustine),followedbyacombinedimmunotherapyapproachusinganautologousdendriticcellvaccine.Informationonthesafetyandtolerabilityofthisregimeninpatientswithadvancedmelanomawillbecollected,whilstobtainingimmunologicaldatacrucialtothedesignoflargerstudiesevaluatingthisapproach.

AnexcitingnewcollaborationwasestablishedwithDrTetsuyaNakatsuraoftheDivisionofCancerImmunotherapyinTokyo,JapanthataimedtoestablishtheclinicalutilityofnoveltumourmarkersSPARCandGPC3formalignantmelanoma.Serumsamplesfromhealthydonorsandourtumourbankwereusedtotestthevalidityofanewassaysystemusingnovelmonoclonalantibodiestothesetumourmarkersandtodeterminetheirincidenceinourpopulation.

Gallipoli M


nu

al Rep

ort 2012 – 2013

10

MyelomaMultiplemyeloma,characterizedbymalignantplasmacellproliferation,bonedestructionandimmunodeficiency,isadiseasewithamedianageatdiagnosisofapproximately65years.Itisresponsibleforabout1percentofallcancer-relateddeathsinWesternCountries.Conventionaltreatmentswithchemotherapyandradiationtherapyarenon-curative,thoughtheydoimprovequalityoflifeandthedurationofsurvival.Aresearchprotocolandapatientinformationandconsentformwerepreparedforatrialwhichaimedtooptimisethetreatmentregimenformultiplemyelomaandprovidethemaximumclinicalbenefitfromcombininghigh-dosechemotherapy,stemcelltransplantation,andimmunotherapy.APhDstudent,MsPriscillaHong(BSc(Biotech),MSc(Biotech))wasawardedajointscholarshipfromtheUniversityofQueenslandandGallipoliMedicalResearchFoundationtocommencethisprojectinOctober2012.Anethicssubmissionwaspreparedandapproved.Recruitmenthasnotyetcommencedonthisstudy.

MesotheliomaMesothelioma,ararecancerusuallycausedbyexposuretoasbestos,currentlyhasapoorprognosis.AcollaborationhasbeenestablishedwithDrKeithHorwood(Oncologist,GreenslopesPrivateHospital)andQueenslandAsbestosRelatedDiseaseSupportSocietytoinvestigatethepotentialofimmunetherapyforthetreatmentofmesothelioma.CITTwassuccessfulinobtainingfundingfromComcareforapilotstudytoevaluatethesafety,feasibilityandimmuneeffectsofstandardchemotherapy(CisplatinandPemetrexed)combinedwithanimmunotherapyapproachusinganautologousdendriticcellvaccineinmesothelioma.Thehopeisthat

thecombinationofchemotherapyfollowedbyimmunetherapywillbemuchmoreeffectivethanthecurrentstandardtherapywhichischemotherapyalone.Whilethereisalreadyfundingforthepreliminarystagesofthisclinicalresearch,furtherfundingisrequiredinorderthatourproposedclinicaltrialcanbecompleted.

DrSteveMattarollo,apostdoctoralscientistwithexperienceinimmunetherapyhascommencedapart-timeappointmentwithintheCITTlaboratorytodirectseveralprojectsandformacollaborativelinkwithanimal-basedresearch.

Statistical Assessment of outcomes of Immune therapy CITThasextensiveexpertiseinthetreatmentofvariouscancertypes,particularlymelanoma,usingimmunetherapy.Astatisticianhascommencedthecollationandanalysisofdatatodeterminetheeffectonsurvivalthathasbeenachievedwiththesetherapies.Continueddevelopmentofourpatientdatabasewillbeundertakensothatprospectivelyvaluabledatawillbecollectedforfutureanalysis.

FacilitiesAnewcellseparationsystem,calledElutra,hasbeenpurchasedbyGMRFwhichwillstreamlinethecollectionofplasmacellsfrombloodafterleukapheresis.OncologynursesfromtheCyrilGilbertCancerCentrehaveundergonetrainingintheuseandmaintenanceofthesystem.Itwillsignificantlyreducethemanualhandlingrequiredfortheisolationofmononuclearcellsrequiredforthepreparationofimmunetherapy.

Research Activities continued

publicationsDengX,TerunumaH,NiedaM,XiaoW,NicolA.(2012)Synergisticcytotoxicityofexvivoexpandednaturalkillercellsincombinationwithmonoclonalantibodydrugsagainstcancercells.IntImmunopharmacol14:593-605

NicolAJ,HagiT,NicolJL,MattarolloS,NiedaM.(2013)Additionofα–GalactosylceramidetotumourpulseddendriticcellvaccinesenhancestumourantigenspecificTcellresponsesandleadstoclinicalresponsesinpatientswithmetastaticmelanoma(in preparation)

NicolAJ,HagiT,NicolJL,NiedaM(2013)Anti-tumourvaccinationinpatientswithmetastaticmelanomafollowingmetronomiclowdosecyclophosphamideforsuppressionofregulatoryTcells(in preparation).

Gallipoli M


nu

al Rep

ort 2012 – 2013

11


Liver Research Unit – led by Professor Darrell CrawfordTheLiverResearchCentrestudiesdisordersofironmetabolism,liverco-toxicityofiron,fatandalcohol,andthecellularbasisofhepaticfibrosisandemergingpotentialanti-fibrotictherapies.ThestrengthoftheLiverResearchCentrereliesonacloseinteractionbetweencliniciansandscientists.This“marriage”ofthebenchandthebedsidehasproventimeandtimeagaintobeaveryeffectivewaytoproducehighquality,clinicallyrelevant,readilytranslatableresearch.

TheLiverResearchCentrehashadaproductive12monthswithProfessorCrawfordnamedtheactingHeadofTheUniversityofQueenslandSchoolofMedicineandelectedPresidentofTheAsianPacificAssociationfortheStudyofTheLiver.ProfessorNathanSubramaniamwaselectedtotheGastroenterologicalSocietyofAustraliaCouncil.TheseachievementsareevidenceofthehighregardforthestaffwithintheLiverResearchCentreinthenationalandinternationalscientificandmedicalcommunities.WehavedevelopedanimportantinternationalcollaborationwithProfessorSaulKarpenofEmoryUniversityintheUSA.Thiscollaborationwillenhancetheprofileofourresearchtoensureitreachesaninternationalaudience.WehavetwoactiveNHMRCgrants-totallingalmost0.6milliondollarsperannum,andareco-chiefinvestigatorsonsixotherNHMRCgrants.Furtherfundingapplicationshavebeensubmittedfor2014.

DrTerenceTanwasawardedhisPhDinDecember,2012.DrTanhaspresentedhisresearchatthehighlyprestigiousAmericanAssociationfortheStudyoftheLiverDiseasemeetinginBoston,2012.MsAmySobbeiscurrentlyfinalisingherPhDthesisforsubmissionandhasagainbeenselectedasafinalistoftheGastroenterological

SocietyofAustraliaYoungInvestigatorAwardstopresentherresearchinMelbourneinOctober2013.MsNishreenSantrampurwalawassuccessfulinconfirmingherPhDenrolmentinJune,2013.WewelcomedanewPhDstudent,DrJanskeReilingfromTheNetherlands.TwoMBBSHonoursstudentsarealsofinalisingtheirfinalassessmentfortheirdegreespriortograduationinDecember2013.TheachievementsofourstudentsandtherecruitmentofnewstudentsisevidenceofthequalityoftheresearchprogrammewithintheLiverResearchcentre.Wewillcontinuetobuildonourdevelopmentsoverthenextyear.Wehaveworld-classfacilities,accesstocuttingedgetechnology,supportfromagenerousandcommittedFoundation,andacommitmenttocollaborationandtheacademicdevelopmentofyoungcliniciansandscientists.

Awards/promotions ProfessorCrawfordnamedtheactingHeadofTheUniversityofQueenslandSchoolofMedicineandelectedPresidentofTheAsianPacificAssociationfortheStudyofTheLiver.

ProfessorNathanSubramaniamwaselectedtotheGastroenterologicalSocietyofAustraliaCouncil.

DrTerenceTanwasawardedhisPhDinDecember,2012.DrTanhaspresentedhisresearchatthehighlyprestigiousAmericanAssociationfortheStudyoftheLiverDiseasemeetinginBoston,2012.

Gallipoli M


nu

al Rep

ort 2012 – 2013

12

GrantsProfessorCrawford,ProfessorSubramaniam,FletcherLandMacdonaldGwereawardedanNHMRCprojectgrant.Title:HFE-associatedSteathohepatitis:MechanismsandTherapies.Amount:$628,765

phD StudentsDrTerenceTanwasawardedhisPhDinDecember,2012.

MsAmySobbeiscurrentlyfinalisingherPhDthesisforsubmissionandhasagainbeenselectedasafinalistoftheGastroenterologicalSocietyofAustraliaYoungInvestigatorAwardstopresentherresearchinMelbourneinOctober2013.

DrLaurenceBrittonwasawardedaGallipoliMedicalResearchFoundationPhDScholarship.

MsNishreenSantrampurwalawassuccessfulinconfirmingherPhDenrolmentinJune,2013andbeingawardedaGallipoliMedicalResearchFoundationPhDScholarshipandaUniversityofQueenslandScholarship.

DrJanskeReilingfromTheNetherlandswhowasawardedthePAResearchFoundations’LiverTransplantResearchAwards–PhDScholarshipandaUniversityofQueenslandInternationalScholarship.

presentations/Abstracts – published AbstractsSobbeAL,BridleKR,deGuzmanCE,SantrampurwalaN,SubramaniamVN,CrawfordDH.DeferasiroxdoesnotexhibitantifibroticactivitywhenadministeredtoMdr2-/-mice.HepatologyInternational,InPress.[PosterofDistinction].

BrittonL,JaskowskiL,WilkinsonA,BridleK,SubramaniamN,CrawfordD.HeterozygousdeletionoftheHfegenecontributestohepaticironloadingbutnotsteatosisinmicefedahighfatdiet.HepatologyInternational,InPress.

BennettNC,McDonaldCJ,Wallace,DF,HooperJD,Lopez-OtinC,SubramaniamVN.ClinicallyidentifiedTMPRSS6mutationsresultineithertraffickingdefectsorinabilitytocleavehemojuvelinAmericanJournalofHematology88E83

McLarenCE,PhatakPD,AdamsPC,SubramaniamVN,BartonJC,GarnerCP,Powell,LW,GurrinLC,AllenKJ,NickersonDA,RammGA,AndersonGJ,McLaren,GD.IdentificationofgenesandvariantallelesassociatedwithironoverloadinhemochromatosisHFEC282Yhomozygotes.AmericanJournalofHematology.88E40.

RishiG,WallaceD,Subramaniam,VN.ProximityligationassaysindicatethathemochromatosisproteinsHFEandtransferrinreceptor2(TFR2)donotinteract.AmericanJournalofHematology.88E202.

SobbeA,FrazerD,BridleK,JaskowskiL,OstiniL,deGuzmanE,SantrampurwalaN,AndersonG,SubramaniamVN,CrawfordD.IsolatedhepaticirondeficiencydespiteabundantsystemicironinMDR2-/-mice:Integrityofthebiliarytransportsystemisimportantinliverironhomeostasis.AmericanJournalofHematology.88E59.

BrittonL,JaskowskiL,WilkinsonA,BridleK,SubramaniamN,CrawfordD.HeterozygousdeletionoftheHfegenecontributestohepaticironloadingbutnotsteatosisinmicefedahighfatdiet.AmericanJournalofHematology.88E204.

McDonaldC,WallaceD,OstiniL,SubramaniamN.DifferentialresponseofthehepcidinregulatorypathwaytooralversusperenteralironinmicelackingHfeandTfR2.AmericanJournalofHematology.88E52-53.


HeritageM,JaskowskiL,WilkinsonAS,BrittonL,TanTC,CloustonAD,BridleK,AndersonGJ,MacdonaldGA,FletcherLM,SubramaniamVN,CrawfordDH.TheprogressionofNAFLDtoNASHinamousemodelofHfe(-/-)-associatedsteatohepatitisisattenuatedbyco-administrationofcurcuminandvitamin.Hepatology.56873A

Tan,TerrenceC.,Crawford,DarrellH.,Jaskowski,Lesley,Santrampurwala,Nishreen,Heritage,Mandy,Subramaniam,V.Nathan,Clouston,AndrewD.,Crane,DenisI.,Anderson,GregoryJ.andFletcher,LindaM.IronToxicityImpairsAutophagyandPromotesERStressinObesityandAlcohol-InducedFibrosingSteatohepatitis.Hepatology,56(Suppl4):294A.

SobbeAL,BridleKR,deGuzmanCE,SantrampurwalaN,SubramaniamVN,CrawfordDH.DeferasiroxdoesnotexhibitantifibroticactivitywhenadministeredtoMdr2-/-mice.JournalofGastroenterologyandHepatology,Vol.27,Supp.4,p.A13.

WilkinsonAS,HeritageML,JaskowskiLA,BrittonLJ,TanTC,CloustonA,BridleK,MacdonaldGA,AndersonG,FletcherLM,SubramaniamN,CrawfordDH.CurcuminandVitaminEcombinationtreatmentreducestheseverityofdiseaseinadiet-inducedmousemodelofNAFLD.JournalofGastroenterologyandHepatology,Vol.27,Supp.4,p.A15.

HeritageML,WilkinsonAS,JaskowskiLA,BrittonLJ,TanTC,BridleK,CloustonA,AndersonG,FletcherLM,MacdonaldGA,SubramaniamN,CrawfordDH.TheprogressionofNAFLDtoNASHinamousemodelofHfe-/--associatedsteatohepatitisisattenuatedbyco-administrationofcurcuminandvitaminE.JournalofGastroenterologyandHepatology,Vol.27,Supp.4,p.A7.

Gallipoli M


nu

al Rep

ort 2012 – 2013

13

presentations/Abstracts – peer Reviewed publicationsTanTC,CrawfordDH,JaskowskiLA,MurphyTL,SantrampurwalaN,CraneD,CloustonAD,SubramaniamVN,AndersonGJ,FletcherLM.ACornOil-BasedDietProtectsAgainstCombinedEthanolandIron-InducedLiverInjuryinaMouseModelofHemochromatosis.AlcoholClinExpRes.2013Jun6.doi:10.1111/acer.12155.[Epubaheadofprint]PMID:23742171

CohenJ,VenkateshB,TanT.ComparisonofthediagnosticaccuracyofmeasuredandcalculatedfreecortisolinacutelyillpatientsusingtheCoolensequation.CritCareResusc.;15(1):39-41.

McDonaldCJ,WallaceDF,CrawfordDH,SubramaniamVN.IronstoragediseaseinAsia-Pacificpopulations:Theimportanceofnon-HFEmutations.JGastroenterolHepatol.2013Jul;28(7):1087-94.

LandersKA,LiH,SubramaniamVN,MortimerRH,RichardK.Transthyretin-thyroidhormoneinternalizationbytrophoblasts.Placenta.34(8):716-8.

JefferyJM,GrigorievI,PoserI,vanderHorstA,HamiltonN,WaterhouseN,BleierJ,SubramaniamVN,MalyIV,AkhmanovaA,KhannaKK.Centrobinregulatescentrosomefunctionininterphasecellsbylimitingpericentriolarmatrixrecruitment.CellCycle12(6):899-906.

OanceaI,PngCW,DasI,LourieR,WinklerI,EriR,SubramaniamN.,JinnahHA,McWhinneyBC,LevesqueJ-P,McGuckinMA,DuleyJA,FlorinTHJ.Anovelmousemodelofveno-occlusivediseaseprovidesstrategiestopreventthioguanine-inducedhepatictoxicity.Gut;62(4):594-605.

KitsonMT,DoreGJ,GeorgeJ,ButtonP,McCaughanGW,CrawfordDH,SievertW,WeltmanMD,ChengWS,RobertsSK.VitaminDstatusdoesnotpredictsustainedvirologicresponseorfibrosisstageinchronichepatitisCgenotype1infection.JournalofHepatology58(3):467-72.

PaulS,StJohnA,O’ReaganK,StuartKA,CrawfordDHG.InteractionofserumferritinandbodymassindexinpatientswithchronichepatitisB:Improvedpredictionofcirrhosis.Hepatology;57(5):2094-5

SubramaniamVN,McDonaldCJ,OstiniL,LusbyPE,WocknerLF,RammGA,WallaceDF.HepaticIronDepositiondoesnotPredictExtra-HepaticIronLoadinginMouseModelsofHereditaryHemochromatosis.Am.JPathol.181:1173-9.

GootK,HazeldineS,BentleyP,OlynykJ,CrawfordD.Elevatedserumferritin–whatshouldGPsknow?AustralianFamilyPhysician;41(12):945-949

LiP,RobertsonTA,ZhangQ,FletcherLM,CrawfordDH,WeissM,RobertsMS.HepatocellularNecrosis,FibrosisandMicrosomalActivityDeterminetheHepaticPharmacokineticsofBasicDrugsinRight-Heart-Failure-InducedLiverDamage.PharmRes;29(6):1658-1669.

CrawfordD,DoreGJ,SievertW,ChengW,WeltmanM,McCaughanG,RawlinsonB,MarksPS,YoshiharaM,RizkallaB.Earlyon-treatmentviralloadandbaselineMETAVIRscore:ImprovedpredictionofsustainedvirologicalresponseinHCVgenotype1patients.AntiviralTherapy17(5):849-54.

TanTC,CrawfordDH,FranklinME,JaskowskiLA,MacdonaldGA,JonssonJR,WatsonMJ,TaylorPJ,FletcherLM.Theserumhepcidin:ferritinratioisapotentialbiomarkerforcirrhosis.LiverInt.;32(9):1391-9.


WallaceD,CrawfordDHG,SubramaniamN.Ironpredictstoleranceinlivertransplantation.Gastroenterology2012;143(3):862-865.

Reiling,J.,Johnson,D.,Kruger,P.,Pillans,P.,&Wall,D.Associationofpre-transplantstatinusewithdelayedgraftfunctioninkidneytransplantrecipients.BMCnephrology,13(1),111.

Book Chapters

CrawfordDHG,FletcherLM,KowdleyKV.IronandLiverDisease.In:AndersonGJ,McClarenGD,eds.IronPhysiologyandPathophysiologyinHumans.:SpringerInternational,2012:441-454.

WallaceDF,SubramaniamVN.Non-HFEHaemochromatosis.In:AndersonGJ,McClarenG,eds.IronPhysiologyandPathophysiologyinHumans:SpringerInternational,2012:399-416.

Gallipoli M


nu

al Rep

ort 2012 – 2013

14


Respiratory Research – Led by Dr Rachel ThomsonTheRespiratoryResearchUnitcontinuestofocusonresearchintoPulmonaryNontuberculousmycobacterialinfectionsandBronchiectasis.BothconditionsarecloselyrelatedandareincreasinginprevalenceinQueensland.Nontuberculousmycobacteria(NTM)areenvironmentalpathogensandareacauseofchroniclungdisease.Thecaninfectpatientswithpre-existingbronchiectasis,andcancauseprogressivebronchiectasisinotherwiseapparentlyhealthypeople.

Thepast12monthshasseenaflurryofpublicationsfromthisunitwiththecompletionoftheThesis“Characteristicsofnontuberculousmycobacteriafromamunicipalwaterdistributionsystemandtheirrelevancetohumaninfections”.

Factorsassociatedwiththeisolationofnontuberculousmycobacteria(NTM)fromalargemunicipalwatersysteminBrisbane,Australia,waspublishedinBMCMicrobiology.ThisisthefirstAustralianstudytodocumentpathogenicmycobacteriaintheBrisbanedrinkingwaterdistributionsystem,andexploressystemandlaboratoryfactorsassociatedwiththepresenceoftheseorganisms.

FromthisDrThomsonandherteamexaminedtheindividualspeciesofNTMfoundinthewaterandcomparedthemtothosefoundinBrisbanepatients.

Mycobacterium abscessusinpotablewater–apotentialsourceofhumaninfectionwaspublishedinBMCInfectiousDiseases,andoutlinesthesimilaritiesbetweenpatientstrainsofM.abscessusandthosefoundinthewater,makingitpossiblethatpatientsmayhaveacquiredtheirinfectionfromdrinkingwaterorshoweraerosols.

this is a major breakthrough in understanding the pathogenesis of these devastating infections. Previouslytheteampublishedasimilarfindingforanotherspecies–Mycobacterium lentiflavum.

IncontrastveryfewstrainsofM. kansasiifoundinwater,matchedthosefoundinpatients.Theteam’sfindingscontradicttraditionalteachingthatthisorganismisa“tapwaterbacillus”.Ifpatientsdoacquireinfectionwiththisorganismfromwater,thenperhapspointsourcecontaminationoccursfromanotherenvironmentalniche.Furtherinvestigationintothisisongoing.AspartofCarlaTolsonsMastersdegree,sheiscomparingthedifferentstraintypingtechniquesusedforcomparingtheseorganisms.ShepresentedherpreliminaryfindingsattheAmericanSocietyofMicrobiologymeetinginDenver.

StrainsofMycobacterium fortuitum(aspeciesthatoftencausessofttissueandwoundinfections)thatwerefoundinwater,werequitedifferentfromthosefoundinpatients,andtheresultsofthisanalysishavebeensubmittedforpublication.

TofurtherevaluatewhetherpatientsacquireNTMinfectionfromwatersourcesintheirownhomestheteamundertookextensivehomesamplingof20patientswithdisease.TheresultsofthisstudywerepublishedintheJournalofClinicalMicrobiology.

TheresearchershavealsopublishedtheirfirstjointpublicationasresultofacollaborationwiththeUniversityofWA–Searchingforanimmunogeneticfactorthatwillilluminatesusceptibilitytonon-tuberculousmycobacterialdisease.HumanImmunology.

Gallipoli M


nu

al Rep

ort 2012 – 2013

15


Theyhavecompletedtheanalysisofanti-cytokineantibodiesinNTMpatients,andthismanuscriptwillbesubmittedintheupcomingweeks.FundinghasbeensecuredtocontinuethiscollaborationandfurtherexploretheimmunesusceptibilitytoNTMinfections.

Asnapshotofthegeographicdiversityofnontuberculousmycobacteriaisolatedfrompulmonarysamples:AnNTM-netcollaborativestudywaspublishedintheEuropeanRespiratoryJournalandmarksthegroup’sfirstcontributiontostudiescoordinatedbytheNTM-net.TheyarecollatingdatatocontributetofurtherstudieslookingatthecumulativeexperiencewithdifferentmedicationsusedtotreatNTMinfectionsacrossmultiplecountries.

WiththecompletionofthelandmarkenvironmentalworkwithNTMinQLD,DrThomsonandhercolleaguesareenthusiastictoembarkonfurtherworklookingattheepidemiologyofNTMinQLDandtheImmunesusceptibilitytotheseinfections.Otherinternationalcollaborationshavebeendeveloped,withWholeGenomeSequencingofM.abscessuscurrentlyunderwayinCambridge,andananalysisofsubspeciesofM.intracellularehasstartedhereincollaborationwiththeUniversityofTexas.InadditiontoCarlaTolson,whoiscompletingaMastersdegree,fourthoracictrainingregistrarsandoneinfectiousdiseasesregistrarareinvolvedintheseresearchprojectsinNTMunderthesupervisionofthisunit.

GrantsDrThomson,Assoc.ProfYang,DrPriceandDrWatererwereawardedaUQ-UWACollaborativeGrant.Title:Anti-cytokineantibodiesinNTMdisease.Amount:$20,000.

DrThomson,Assoc.ProfYang,DrPriceandDrWatererwereawardedaUQAcademicTitleHolderGrant.Title:InnateImmunityinNRMdisease.Amount:$19,851.

StudentsDrRachelThomson’sPhDiscurrentlyunderexternalexamination.

MsCarlaTolsonisprogressingwithherMastersdegree.

peer Reviewed publicationsRachel thomson, Carla tolson, Flavia Huygens, Megan Hargreaves. StrainvariationamongstclinicalandpotablewaterisolatesofM. kansasiiusingautomatedrepetitiveunitPCR.Submittedto International Journal of Medical Microbiology (IJMM-D-13-00047)Feb2013(ReturnedforrevisionJuly2013)

Rachel thomson, Carla tolson, Chris Coulter, Flavia Huygens, Megan Hargreaves. IsolationofNTMfromhouseholdwaterandshoweraerosolsinpatientswithNTMpulmonarydisease. Journal of Clinical Microbiology published online ahead of printJuly10,2013

Affandi, J. S.; Hendry, S.; Waterer, G.; thomson, R.; Wallace, H.; Burrows, S.; price, p.:Searchingforanimmunogeneticfactorthatwillilluminatesusceptibilitytonon-tuberculousmycobacterialdisease.Human Immunology.June2013epubaheadofprint

Rachel thomson, Carla tolson, Robyn Carter, Flavia Huygens, and Megan Hargreaves.FactorsassociatedwiththeisolationofNontuberculousmycobacteria(NTM)fromalargemunicipalwatersysteminBrisbane,Australia.BMC Microbiology2013,13;89doi:10.1186/1471-2180-13-89

Rachel thomson, Carla tolson, Flavia Huygens, Megan Hargreaves.Mycobacterium abscessusinpotablewater–apotentialsourceofhumaninfection.BMC Infectious Diseases2013;13;241

W. Hoefsloot, J. van Ingen*, C. Andrejak, K. Ängeby, R. Bauriaud, p. Bemer, M.J. Boeree, J. Cacho , e. Chimara, R. Cias, R. Dasa, p.n.R. Dekhuijzen, D. Domingo, F. Drobniewski, J. esteban, M. Fauville-Dufaux, D.B. Folkvardsen, n. Gibbons, e. Gómez-Mampaso , R. Gonzalez , H. Hoffmann, p.R. Hsueh, A. Indra, t. Jagielski, F. Jamieson, M. Jankovic, J. Keane, W.J. Koh, S. leao, R. Macedo, t. Mannsåker, t. Marras, J. Maugein, H. Milburn, t. Mlinkó, n. Morcillo, K. Morimoto, D. papaventis, e. palenque, M. paez-peña, C. piersimoni, M. polanová, n. Rastogi, e. Richter, M.J. Ruiz-Serrano, A. Silva, H. Simsek, D. van Soolingen, n. Szabó, R. thomson, M.t. tórtola Fernandez, e. tortoli, S.e. totten, G. tyrrell, t. Vasankari, M. Villar, R. Walkiewicz, K. Winthrop, D. WagnerforNTM-NET.Asnapshotofthegeographicdiversityofnontuberculousmycobacteriaisolatedfrompulmonarysamples:AnNTM-netcollaborativestudy.European Respiratory JournalApril18,2013(epubaheadofprint).

Gallipoli M


nu

al Rep

ort 2012 – 2013

16


GMRF Clinical Trials Unit – Managed by Miriam Dwyer TheGMRFClinicaltrialsunitcoordinatesPhaseIIandIIIstudiesprimarilyincancer(melanoma,ovariancancer,pancreaticcancerandlymphoma)andHepatitisC.

Theunitisuniqueinitsmanagementstructureunderanagreementwiththeclinicians,thehospitalandthefoundation.Thetrialsarecoordinatedeffectivelybydedicatedstaffemployedbytheresearchfoundationwithallprofitsbeingreturnedtothefoundationtosupportfurtherresearch.

ThefoundationmanagesthespecificelementsofthetrialprocessallowingthecliniciansatGreenslopesPrivateHospitaltomanagetherequirementsoftheprotocolandthemedicalcareofthepatientsonthestudies:

TheClinicalTrialsUnitisresponsiblefor:

• Studysetupincludingstudyfeasibility

• Contractandbudgetnegotiation

• Ethicsapplicationsandregulatorysubmissions

• Patientcoordinationandcompliancewiththeprotocol

• Datacollectionandprocessing

• Liaisonwith3rdpartysuppliers(radiology,pharmacy,pathologyetc)

• Studycloseoutandarchiving.

TheFoundationalsosupports“investigatorinitiatedresearchprojects”conductedatGreenslopesPrivateHospitalandallresearchisreviewedandapprovedbytheGreenslopesPrivateHospitalEthicsCommitteebeforeproceeding.

Wound Care Project TheGMRFwoundcareprojectentereditssecondphasein2012.AfurthergrantwasapprovedbytheWoundCRCtoinvestigatewhethertwicedailymoisturisationofarmsandlegswillimproveskinintegrityandresultinfewer,lesssevereskintears.Thisstudywilltakeplaceoveraperiodof12monthsintheFlorenceSyerandRehabilitationWardsofGreenslopesPrivateHospital.Itishopedthatthisresearchstudywillshowthissimple,lowriskinterventiontobeaneffectivewayofdecreasingthepainandsufferingassociatedwiththesewounds.Todate,704patientshaveconsentedtoparticipateinthepreventiontrial.Regularmoisturisationhasbeenpositivelyreceivedbypatientsandstaffandisshowingpromisingresults.Thetrialisdueforcompletiononthe10thNovember2013.

Research Grants Awardedtitle: evaluation of Chemotherapy followed by Multivalent Dendric Cell Vaccines and Ipilimumab for Stage IV Metastatic Melanoma.

• ChiefInvestigator–AssociateProfessorAndrewNicol

• Amountawarded–$100,000

title: evaluation of clinical and immunological effects of anti-myeloma vaccination and autologous cytotoxic cell infusions following immune modulating remission induction therapy

ChiefInvestigator–AssociateProfessorAndrewNicol

• ChiefInvestigator–AssociateProfessorAndrewNicol

• AmountAwarded–$100,000

Gallipoli M


nu

al Rep

ort 2012 – 2013

17


GPH Innovation Grants 2012“It really surprised me how all the staff went out of their way to ensure that they did everything they could to see that my stay in hospital would be one that I will recall with very good memories.” Patient from Ward 21, Greenslopes Private Hospital

Thepositiveimpressionthatapatientleaveshospitalwithislargelyduetotheoutstandingcaretheyreceivedfromnursesandalliedhealthprofessionals.Afterspendingyearsonthefrontline,manyofthesededicatedindividualsseepracticalopportunitiestoimprovepatientcare.

Withthedemandsoftheirbusyschedule,nursesandalliedhealthprofessionalsdonotalwayshavethetimeandresourcestoexploretheirideas.Seeingtheopportunitytotapintothiswealthofideastoimprovepatientcare,GMRFdevelopedthenew Research Innovation Grants for nurses and Allied Health professionals.

Applicationswereofaveryhighstandardfortheinauguralgrants,whichwereheldduringGMRFRemembranceThroughResearchWeek2012.DuetothegenerosityofGMRFsupporters,wewereabletoinvestingrass-rootsresearchsuchas:

• $9,000 grant awarded to the ADApt program,whichisaneducationandphysicalactivityprogram,designedtoencouragehealthylifestylebehaviorsamongveteranswithmentalillness.

• $7,000 grant awarded tothedevelopmentofprotocoltoreduceperipheral Inserted Central Catheter (pICC) relatedinfectionsinadultpatientsinanacutecaresetting.

• $7,000 grant awardedtoreviewingandrefiningthecurrentproceduresaroundtreatmentlimitingdecisionsandnot for resuscitation(NFR).

• $7,000 grant awarded toaprojectwhichaimstoimprove nutritional care to improve clinical outcomes for orthopedic patients with hip related injuries.

AtGMRF,wearecertainthatthesenursesandalliedhealthprofessionalsaregoingtodiscoverpracticalnewthingsthatwillhavearealimpactonpatientcare.Thankyoutoallofourdonorswhomadethisinitiativepossiblethroughyourcontinuedsupport.

PHD Scholarships Awardedthesis title: HFe-associated Steatohepatitis: mechanisms and therapies (Second Year Funding)

• NameofCandidate–NishreenSantrampurwala

thesis title: understanding the role of hepcidin and other factors associated with iron overload in non-HFe liver disease (Second Year Funding)

• NameofCandidate–DrLaurenceJamesBritton

thesis title: Sequential anti-myeloma vaccination, autologous stem cell transplant (ASCt) and adoptive t cell therapy with post transplant vaccination for treatment of multiple myeloma (1st year of top up scholarship)

• NameofCandidate–MsPriscillaHongBSc(Biotech)(Hons),MSc(Biotech)Withdrew from the project in March 2013

Gallipoli M


nu

al Rep

ort 2012 – 2013

18

Board of Directors1 Mr paul Ramsay AO (Patron)

MrPaulRamsayhasbeeninvolvedinhealthcaresince1964whenhedevelopedandmanagedoneofthefirstprivatepsychiatrichospitalsinSydney.AsChairmanandmajorshareholderofRamsayHealthCareLimited,hehasdevelopedRamsayHealthCareintoAustralia’slargestprivatehospitalgroup.Today,theCompanyownsandoperates116hospitalsandfacilitiesacrossAustraliaandoverseas.MrRamsayisalsoChairmanofPrimeMediaGroupLimited,whichoperatesintelevision,radioanddigitalnewmedia.In2002,MrRamsaywasconferredanOfficeroftheOrderofAustraliaforservicestothecommunitythroughtheestablishmentofprivatehealthcarefacilities,expandingregionaltelevisionservicesandasabenefactortoarangeofeducational,cultural,artisticandsportingorganisations.

2 Mr tom Ryan (Chairman) B Pharm, FAICD, FACP

MrTomRyanisaformerDirectorandChairmanofAustralianPharmaceuticalHealthcareSystems(APHS).MrRyanwasafoundingpartneroftheAPHSGroup.TheAPHSgroupprovidespharmacyserviceswithinprivatehospitals,aswellasprovidingoncologyservicestoavarietyofpublicandprivatehospitalsandalsoprovidinganextensiveservicetoagedcarefacilitiesforbothprescriptionsupplyandclinicalconsultancies,andcommunitypharmacyservices.MrRyanownedandoperatedthepharmacyserviceatGreenslopesPrivateHospitalfrom1995until2010.

3 Associate professor David ColquhounAssociateProfessorDavidColquhounisaCardiologistinprivatepractice.Hehasbeenextensivelyinvolvedinresearchoverthelast25yearsinvolvingmulti-centreinternationaltrialsandinvestigatorinitiatedtrialsintheareaoflipids,nutrition,nutraceuticalsandphysiologicalaspectsofheartdisease,diabetesandobesity.Hehaspresentedhisresearchatmanynationalandinternationalmeetings.HehasbeenHeadofCardiovascularresearchatGreenslopesPrivateHospitalsince1999.Hehasaprivateresearchorganisation(COREResearch).

Hehaspublishedandbeenarefereeformajorjournals.HeistheAMAspokespersonforCardiologyinQueensland.HeisamemberoftheScientificCommitteeofNationalInstituteofComplementaryMedicine.In2008heattendedthe2020SummitnominatedbytheNationalHeartFoundationandwastheonlycardiologistatthesummit.HewasamemberoftheQueenslandGovernmentSmartStateCouncilworkinggrouponpreventionandearlyinterventionapproachestotacklechronicdisease.

HeisagrantassessorforNationalHealthandMedicalResearchCouncil,NationalHeartFoundationAustraliaandDiabetesAustralia.

HewasamemberoftheNationalHeartFoundationofAustraliaNutritionandMetabolismCommittee.HewastheChiefAuthoroftheNationalHeartFoundation’spositionstatementonfishandfishoilin2008.HeistheChairoftheNationalHeartFoundation’sPsychosocialRiskFactorsandCoronaryHeartDiseaseExpertCommittee.

1

3

2

Gallipoli M


nu

al Rep

ort 2012 – 2013

19

3 Mr Stephen CopplinStephenistheManagingDirectoroftheCFOCentrePtyLtd.

Hisprofessionalcareerspansnumerousindustrysectors,includingfinance,insurance,investmentbanking,technology,mediaandcreativeindustries.Duringhistime,Stephenhassuccessfullymanagedfinanceoperationsformulti-nationalcorporations,negotiatedmulti-milliondollarinternationalacquisitionsanddivestmentsandbuiltstart-upsfrominceptionthroughtotradesale.

StephenisaFellowCertifiedPracticingAccountant,AFellowoftheAustralianInstituteofCompanyDirectorsandheisanAdjunctProfessorintheSchoolofBusinessandtheSchoolofElectricalEngineeringattheUniversityofQueensland.

AsaprofessionalCompanyDirector,hecurrentlyholdsanumberofnon-executiveboardpositionswithbothpublicandprivatecompanies.

4 professor Ken DonaldOriginallytrainedasaPathologist,KenDonaldhashadappointmentsasanAcademicPathologist,DirectorofPathologyatRoyalBrisbaneHospitalandlateratHunterAreaPathologyServices,andProfessorofAnatomicalPathologyatTheUniversityofNewcastle.Thenfollowedpost-doctoralstudiesatErasmusUniversityRotterdamandEdinburghUniversityScotland.HehasalsobeenDeputyDirector-GeneralofHealthinQueensland(foradecade)andinthe1990’swasProfessorandHeadoftheDepartmentofSocialandPreventiveMedicineatTheUniversityofQueenslandandwas,untilthe31stDecember2006,HeadoftheSchoolofMedcine.Hehaschairedanumberofmajornationalauthoritiesand

committeeswithinNHMRC,AIDSControl,CancerControlandVeterans’CompensationSystems.InrecentyearshehasbeenDirectorofMedicalServicesatRoyalDarwinHospitalandMedicalAssistantCommissionerontheHealthQualityandComplaintsCommissioninQueensland,andrecentlyretiredasChairoftheRepatriationMedicalAuthorityintheWarVeteransCompensationSystemafternineteenyears.HehaspublishedextensivelyinmedicalliteratureandTextbooks.In2009/10hewasDirectorofMedicalServicesatKatherineHospital,NorthernTerritory.HehasrecentlybeenappointedProfessorofAssessmentandEvaluationatGriffithUniversityMedicalSchool.HehasleadenquiresforQueenslandHealthwhichinvolvedpost-graduatetraining,registrationofoverseasdoctorsandworkforcesupplyandcurrentlyCancerServicesandPublicHealthResearch.In2007hewasmadeanofficeroftheOrderofAustralia(AO),andinJune2012receivedthePremier’s2012QueenslandGreatAward.

5 professor nicholas M Fisk (resigned April 2013)

ProfessorNicholasFiskiscurrentlyExecutiveDeanoftheFacultyHealthSciencesattheUniversityofQueensland.HewastheinauguralDirectoroftheUQCentreforClinicalResearchin2008/09,andpreviouslybetween1992and2007wasProfessorofObstetricsandFetalMedicineatImperialCollegeLondon.ProfessorFiskiswidelypublishedinclinicalmedicineandbiomedicalsciencewithresearchinterestsinfetalstembiologyandtherapy,fetalnociception/stressresponsiveness,andmonochorionicplacentation.

Board of Directors continued

5

3 4

Gallipoli M


nu

al Rep

ort 2012 – 2013

20

9 Dr peter Kortlucke MBBS, FRACGP (resigned 17 April 2013)

Director,RehabilitationUnitGPH,HeadofGeneralandGeriatricMedicineatGPHandHeadofStrokeUnitGreenslopesPrivateHospital.

10 Mr David McDonald FIPA(resigned 26 Sept 2013)

MrDavidMcDonaldistheGeneralManagerinBrisbanefortheFairfaxRadioNetworkradiostations11164BCand8824BH.MrMcDonaldisoneofRadio’smorerespectedandexperiencedoperatorsandhasalsosuccessfullyoperatedhisownbusinessconsultancy.Hehasworkedbothoverseasanddomestically.PriortothathewasGeneralManageroftheAustralianRadioNetworks’StationsinMelbourne.InadditionhehassuccessfullymanagedAustereo’sMelbournestationsTripleMandFOX.Priortothishesuccessfullymanaged3AW.MrMcDonaldbeganhismediacareerin1984asNetworkFinanceManagerfortheAWABroadcastingDivision.HewasalsoFinancialControllerfortheWesgoRadioGroup.PriortohismediacareerhemainlyworkedinEngineeringandManufacturingindustries.

11 Dr David McMaugh (resigned 30th July 2013)

DavidMcMaughpossessesaverywidebackgroundofexperienceinclinicalpractice,healthmanagementandhealthleadership–fromactingCEOoftheRoyalBrisbaneHospital,tointernationalhealthaccreditorwithACHS,toUniversityteacher.Heisowner/CEOofLeadershipHealthServices,aboutiqueandfocusednicheconsultancygroup.DavidisalsoCEOofBunjurgenEstateVineyardandconsultsforCommunioPtyLtdworkingwithbothprivate,notforprofitandgovernmentagenciesincludingtheADF.HeservedinAustraliaandtheUKasanOfficerintheAustralianArmyfrom1964to1991(27years).


6 Mr John Gallagher QC

MrJohnGallagherwasadmittedtotheQueenslandBarin1964andbecameaQueen’sCounselin1982.MrGallagherwasanABCBoardMemberbetween1999and2008andwastheDeputyChairmanoftheABCfrom2005to2008.During1991heheldthepositionofActingDistrictCourtjudge.HewastheChairmanofRetailShopLeasesTribunalQueenslandbetween2002and2005.

7 Mr Cyril Gilbert OAM

MrCyrilGilbert,well-knownQueenslander,remainsahighprofileadvocateandmentorfortheveterancommunitysincereturningfromwarin1945.MrGilbertisanexPrisonerofWar(POW)whohasachievednationalrecognitionfortheveteranandexPOWcommunity.HewasawardedanOAMforhisservicestotheveterancommunityin1983andaCentenaryAwardin2003.MrGilbertisalsoamemberoftheGreenslopesPrivateHospitalExServiceOrganisation(ESO)Committee.

8 Dr Michael Harrison MBBS, FRCPA

DrMichaelHarrisonistheChiefExecutiveOfficer/ManagingPartnerofSullivanNicolaidesPathologyandisaConsultantPathologistatthemainTaringaLaboratoryintheareasofClinicalChemistryandMicrobiology.DrHarrisongraduatedfromtheUniversityofQueenslandin1977withanMBBS(1stClassHonours)andin1984wasawardedFRCPA(GeneralPathology).

DrHarrisonisthePresidentofAustralianAssociationofPathologyPractices,OldStateCouncillorfortheRCPA,ChairmanoftheMedicalTestingAccreditationAdvisoryCommitteesince1999,andChairmanoftheQualityUseofPathologyCommitteesince1999.HehaspresentedatmanynationalandinternationalmeetingsonthetopicsofQuality,LaboratoryManagementandeHealth.

10 11

8 9

76

Gallipoli M


nu

al Rep

ort 2012 – 2013

21

14 professor John pearn AO RFD

MajorGeneralJohnPearnisoneofAustralia’smostseniordoctor-soldiers.

AsProfessorPearn,heistheSeniorPaediatricianattheRoyalChildren’sHospitalinBrisbane,wherehehasbeenafull-timestaffmembersince1968.Hismajorinterestsinpaediatricsandinternalmedicinehavebeeninmedicalgenetics,clinicaltoxicologyandaccidentprevention.MajorGeneralJohnPearnalsoservedinasecondcareerintheAustralianDefenceForce,risingprogressivelythroughvariousseniorcommandandexecutivepositionsintheDefenceHealthServicepriortobeingpromotedtotherankofMajorGeneralandappointedasSurgeonGeneraltotheAustralianDefenceForce.Heservedinthisroleuntilhisretirementin2000.

15 Mrs Jean pockettMrsJeanPockett,amemberoftheWarWidowsGuildsince1970,isalongstandingStateCouncilmemberandisapastVicePresidentoftheGuild,apositionsheheldonfouroccasions.ShehasattendednumerousnationalConferencesandbeentheGuild’sdelegatefortheex-ServiceOrganisations.MrsPocketthasservedontheExecutiveCouncilandhasbeenamemberofthesocialcommittee.

SheisamemberoftheGreenslopesPrivateHospitalExServiceOrganisation(ESO)CommitteewheresherepresentsthewholeofQueensland.InadditiontoworkingvoluntarilyintheStateOfficeoftheGuildsheisveryfamiliarwiththecampusatGreenslopesPrivateHospitalwhereshehasvolunteeredasahospitalvisitorformorethantwentyyears.Hervolunteerworkwasrecognisedin2012whenshewaspresentedwitha40yearVoluntaryServiceCertificatebythehospitalexecutive.ShewasaninauguralboardmemberoftheGallipoliMedicalResearchFoundation.SheisalsoamemberoftheQueenslandCricketers’Club.


12 Ms Carmel Monaghan (Company Secretary) BBusComm, MBA

MsCarmelMonaghanistheMarketingandPublicAffairsManagerforRamsayHealthCare.RamsayHealthCareisAustralia’slargestoperatorofprivatehospitalsandalsooperateshospitalsintheUnitedKingdom,France,MalaysiaandIndonesia.AsMarketingandPublicAffairsManager,MsMonaghan’sroleencompassesbrandrecognition,corporatemarketing,group-widecommunication,andbusinessdevelopment.Shehasextensiveexperienceinrebrandingacquisitions.Shehashadastrongfocusinhealth-relatedmarketingandpublicrelations,beingpreviouslytheManagerPublicRelationsandMediafortheQueenslandBranchoftheAustralianMedicalAssociation(AMAQ)andtheMarketingandBusinessDevelopmentManageratGreenslopesPrivateHospital.ShehasbeeninhercurrentroleasGroupMarketingManagerforRamsayHealthCaresince2002.

13 Mark page (Deputy Chairman) BBus

Markhas13yearsseniormanagementexperienceintheprivatehealthsector,eightashospitalCEOacrossdiversesettingsthroughoutAustralia.InJune2011MarkwasappointedtothepositionofCEOofGreenslopesPrivateHospital.With677licencedbedsand16operatingtheatres,GreenslopesPrivateHospitalisAustralia’slargestandmostcomprehensiveprivateteachinghospital.Markhasrecentlyoverseena$50MexpansionofGreenslopesPrivateHospitalwhichprovidedthehospitalwithanadditionaltwooperatingtheatres,106additionalbedsandthecreationoftheGreenslopesPrivateHospitalmaternityandneonatalservice.PriortohisappointmentatGreenslopes,MarkwastheCEOofRamsayCairnswherehecommissionedFarNorthQueensland’sfirstInterventionalCardiologyserviceanddevelopedTheCairnsClinic,thefirstdedicatedPrivateAcutePsychiatricHospitalnorthofBrisbane.

17 1812 13

1514

Gallipoli M


nu

al Rep

ort 2012 – 2013

22

18 professor Ross Young ProfessorRossYoungwasappointedExecutiveDean,FacultyofHealthQUTinJanuary2013followingsevenyearsasExecutiveDirector,InstituteofHealthandBiomedicalInnovation(IHBI),QUT.

ProfessorYoungisaClinicalPsychologistandhisresearchinterestslieintheintegrationofpsychologicalandbiologicalriskfactorsinmentalillness.Hisresearchincludesworkinsubstancemisuse,schizophrenia,anxietydisordersandmorebroadlyinbehaviouralmedicine.Thisincludesworkinpharmacogenomicsandthedevelopmentofpersonalisedmedicineviatheuseofgenechips.ProfessorYounghasover190publishedpapersingenetic,medical,psychiatricandpsychologicaljournals.ThisincludesworkinprestigiousjournalssuchasNatureMedicine.


16 Ms toni thornton MsToniThorntonisanExecutiveDirectorwithJBWereinaninvestmentadvisorycapacitytolargeNon-Profitgroups,listedexecutivesandUltraHighNetWealthfamilies.ToniistheformerStateManagerQueenslandandExecutiveDirectorofGoldmanSachsJBWere.MsThorntonholdsaBachelorofArtswithaPoliticsmajorandminorinEconomicsandalsoholdsanumberofpostgraduatequalificationsincludingAppliedFinanceandderivativesaccreditations.SheisaresponsibleexecutiveoftheASX,hasundertakenanAcceleratedExecutiveManagementprogramthroughtheAGSMandhascompletedtheGoldmanSachsJBWerenon-profitleadershipprogram.ShehasbeenwithGoldmanSachsJBWereandJBWereforover15yearsinInvestmentAdvisoryrolesinSydney,aStrategicManagementroleinMelbourneworkingalongsidetheManagingDirector–PWMandinBrisbanewhereshewastheStateManagerforsevenyears.MsThorntonpreviouslysatontheboardoftheSouthBankCorporationandtheSouthBankCorporationauditcommitteefor5years.

17 Mr pat WelshMrPatWelsh,SevenNewssportsreporterandpresenter,isoneofAustralia’sleadingsportsjournalistsandcommentators,withmorethan35yearsexperience.MrWelshisbestknownforhisrugbyleagueandgolfingcommentaryandhehastravelledextensivelythroughoutEurope,AustraliaandtheUnitedStatesfortheSevenNetwork.Hehascoveredthelast8(SummerandWinter)OlympicGamesfrom1992–2008.

17

18

16

Gallipoli M


nu

al Rep

ort 2012 – 2013

23

CommitteesGMRF Fundraising SubcommitteeMembers MsToniThornton(Chair)

AssProfDavidColquhoun

MrPatWalsh

MrStephenCopplin

GMRF Finance and Audit SubcommitteeMembers MrStephenCopplin(chair)

MrJohnGallagher

MrTomRyan

GMRF Research and Governance SubcommitteeMembers ProfRossYoung(Chair)

AssProfDavidColquhoun

ProfDarrellCrawford

DrMichaelHarrison

ProfKenDonald

ProfessorBruceAbernethyBHMS(Ed),PHD

GMRF Clinical Review Committee edwin Anthony Blackwell, MBBS,FRACp, FRCpA

SeniorLecturer,DepartmentofMedicine,theUniversityofQueensland;ConsultantPhysicianinClinicalHaematologyandMedicalOncology,GreenslopesPrivateHospital.

Glenda Joyce powell, AM, MBBS, FRCp (edin), FRACp, FAFRM

EmeritusConsultantinGeriatricMedicineandRehabilitation,GreenslopesPrivateHospital;EmeritusatPrincessAlexandraHospital;PrivatePractice–Medico-Legal.

Christopher Robin Strakosch, MD,FRACp

ConsultantEndocrinologist,GreenslopesPrivateHospital;AssociateProfessorandHead,DisciplineofMedicine.UQ,GreenslopesCampus.

prof Mike Whitby

ProfWhitbyisanInfectiousDiseasesPhysician/Microbiologist.HeisProfessorofMedicine,UniversityofQueensland,GreenslopesClinicalSchool,andProfessor,andClinicalDirector,CREinReducingHealthCareAssociatedInfections,InstituteofHealthandBiomedicalInnovation,QldUniversityofTechnology.

Gallipoli M


nu

al Rep

ort 2012 – 2013

24

Acknowledgements Platinum PlusCorporate ReturnedandServicesLeagueAustralia,Queenslandbranch

RSl/Veteran/Service organisations DiggersDozenVolunteers,GreenslopesPrivateHospital

Individuals MrandMrsJohnandWendyThorsen

MrsNormaJeanBracken

MrandMrsBrettandZahraGodfrey

MrsElaineFeddersen

Platinum CorporateRamsayHealthCare

APHS

SullivanNicolaidesPathology

UniversityofQueensland,FacultyofHealthSciences,SchoolofMedicine

MedinetCoLtd

RSl/Veteran/Service organisationsWarWidows’GuildofAustralia(Qld)Inc

Kedron-WavellServicesClubandKedron-WavellSub-BranchRSL

IndividualsMrandMrsRogerTrundle

ProfessorDarrellCrawford

DrRolandNoakes

MrsBettyBuising

Gold CorporateQMLPathology

PhilipsMedicalSystems

JohnsonandJohnsonMedical

QueenslandX-Ray

StrykerAustralia

Olympus

SpotlessGroupLimited

DeviceTechnologiesAustralia

MedtronicAustralasiaPtyLtd

BaxterHealthcare

RocheProductsPtyLtd

QueenslandUniversityofTechnology

RSl/Veteran/Service organisationsSherwood-IndooroopillyRSLSub-BranchandSherwoodServicesClubInc

GreenbankRSLServicesClub

GreenbankRSLSub-Branch

RedlandsRSL

CoorparooandDistrictsRSLSubBranch

StephensRSLSubBranch

GreenbankRSLSubBranchWomen’sAuxiliary

Community organisationsGill’sOldBastards

Individual Supporters 2012/2013

$5,000+MrsSusanLUnsworth

MrsPearlELogan

MrsMargaretBrodie

MrsMaryBoydell

ProfessorRichardGordon

MrMalcolmBroomhead

$1,000–$4,999DrKeithHorwood

MrsLynetteBarnett

MrPeterDarmody

MrWilliamPatrick

MrsJulianneKiellly

MissEricaRasche

MrsJeanThompson

MrRobertGreenelsh

MrRobinHarvey

MrStewartGow

MrGeoffreySattler

DrJeffGoh

$500–$999MrsAlmaWilliams

MrsHelenduFrocq

MsBerylHawdon

MrReginaldMonks

MsBeverleyEdgar

MrsElenaCartmell

MrsGwenythBodger

MrsTeresaTodhunter

MrEdwinPearson

MrandMrsD.PandM.AWilkinson

MrRobertGordon

MrsJoyeTrundle

MrRobertIngpen

MrDLutton

MrsLyndaSugars

MrBillWheeler

MrsJuneBerry

MrJohnRumble

MrVivianByatt

MrsJackieDennis

MrsMargaretKnight

MrBruceDennison

MrsRosemaryGoodsall

MrDouglasCowlishaw

MrsBarbaraDMurphy

MrGeorgeHall

MrsElizabethSmith

MrsBettyYoung

MrsMichelleFitzpatrick

Gallipoli M


nu

al Rep

ort 2012 – 2013

25

Discovery Partner MrsMarjorieTrundle

MrandMrsRobertandBernadetteNey

MrandMrsTerryandCamillaBarker

Cyril Gilbert Testimonial Fund platinum GreenslopesPrivateHospital

MrPaulRamsayAO

TheQLDExPrisonerofWarAssociation

MrandMrsBlairandJoySmithandJoanneLesleyUsher

Gold RSLQueensland

Silver SullivanNicolaidesPathology

DiggersDozen–GPH

Bronze MrCyrilGilbertOAM

AssociateProfessorAndrewNicol

MrRichardLizzio

MsCarmelMonaghan

RedlandsRSL

MrPatWelsh

DrPretoriaBilinski

MrsAnneMareeWright

In kind support for events, auctions and rafflesMrPatWelsh

GPH–DiggersDozen

TheMarketingTeamatGreenslopesPrivateHospital

ThePayrollTeamatGreenslopesPrivateHospital

TheITTeamatGreenslopesPrivateHospital

DrJeffDeslandes

GreenbankRSL

MrsThereseSmith

HelenduFrocu

BreannaHickling

AlmaWilliams

DougMurray

Roy’sGolfDay

MsChakaeD’EllenCourt

CaledonianLodge

LynndonLadiesBowlingClubInc

MrandMrsAdamandAllisonDeVries

WantimaThursdayLadiesGolfClub

VolunteersGallipoliMedicalResearchFoundationvaluesthetremendoussupportoftheDiggersDozenandCareVolunteersatGreenslopesPrivateHospital.

Estates, Trusts and FoundationsEstateofMrsMaryHinkley

TheHondaFoundation

StateTrusteesAustraliaFoundation

JamesNKirbyFoundation

EstateofMsMarjorieEastman

EstateofJeremiahCoffey

GoldmanSachsJBWereFoundation

CoryCharitableFoundation

EstateofMrsJosieClareGrinsell

EstateofMrVictorJohnBahr

ThefamilyofDickandElsieHagerty

EstateofShirelleNahow

MrGD(Doug)Murray

TheCancerCouncil

QueenslandCommunityFoundation

MandJMcCormickfamilyTrust

EstateofJoyceSmith

TheLoganFamilyFoundation

EstateofMrMarkKelly

In Memoriam MichaelAStorah(InMemoriam)

InMemoriamofMrJohnLeslieHarrison

InmemoryofMrsMayYoung

LouJuraszko(InMemoriam)

InmemoriamofMrJackOliphant

InmemoryofMrLeslieFrancisSmith(exP.O.W.)

InMemoryofMrsGertFrancis

InMemoryofMsAdeleRadke

MrsGemmaMinto

MrBrianJohnBrandenburg

Acknowledgements continued

Gallipoli M


nu

al Rep

ort 2012 – 2013

26

Gallipoli Medical Research Foundation ACN: 077 750 693 Financial Statements for the Year Ended 30 June 2013

Contents

27 Directors’ Report

31 Auditor’s Independence Declaration under Section 307C of the Corporations Act 2001

32 Statement of profit or loss and other Comprehensive Income

33 Statement of Financial position

34 Statement of Changes in equity

35 Statement of Cash Flows

36 notes to the Financial Statements

48 Directors’ Declaration

49 Independent Audit Report to the members of Gallipoli Medical Research Foundation ltd

Financial Statements for the year ended 30 June 2013

Gallipoli M


nu

al Rep

ort 2012 – 2013

27


YourdirectorspresenttheirreportontheCompanyforthefinancialyearended30June2013.

DirectorsThenamesofthedirectorsinofficeatanytimeduring,orsincetheendof,theyearare:

names position Appointed/Resigned

MrThomasRyan Chairman

MsCarmelMonaghan Secretary

ProfessorJohnPearnAO

MrJohnGallagherQC

MsToniThornton (MaternityLeaveduring2013)

MrsJeanPockett

MrPatWelsh

MrDavidMcDonald

DrMichaelHarrison

MrCyrilGilbertOAM

ProfessorRossYoung

AssociateProfessorDavidColquhoun

MarkPage Appointed17April2013

DrDavidMcMaugh Resigned20June2012

ProfessorKenethDonald Appointed19November2012

MrStephenCopplin Appointed19November2012

ProfessorNicholasFisk Resigned17April2013

DrPeterKortlucke Resigned17April2013

MrDavidMcDonald Resigned26September2012

Directorshavebeeninofficesincethestartofthefinancialyeartothedateofthisreportunlessotherwisestated.

Directors’ Report 30 June 2013

Company SecretaryMsCarmelMonaghanheldthepositionofcompanysecretaryattheendofthefinancialyear,sheisalsoadirectorandherdetailsandqualificationsaresetoutlaterinthisreport.

our VisionWebelievethatthediseaseswhichindiscriminatelyaffectboththeyoungandold,canandmustbeconqueredinourlifetimethroughmedicalresearch.Inourvitalworkoffacilitatingdiscoveries,werememberandtakeinspirationfromthedisciplineanddedicationexemplifiedbyourveterans.

GMRF foundation missionGMRF’ssupportersholdadeepbeliefthatmedicalresearchcanchangelives.Weaimtoturntheirbeliefintobreakthroughsbyraisingandinvestingfundsintotheinnovativescientificdiscoveriesoftomorrow.Weensurethatourscientistshavethetime,spaceandresourcesrequiredtofindnewwaystosavelives.

GMRF research missionGMRFisdriventoimprovehumanhealthbyidentifyingandexploringtheblackholesincurrentscientificknowledge.Beyondtheboundariesoftoday’streatments,wesearchforanswerstothemostchallengingmedicalquestions.Thedepthandqualityofthisresearchisaresultofrelentlesslyfocussingonourstrengthsandspecialisations.Webringtogetherthebestideasandindividualsinpursuinggamechangingdiscoveries.

our Strategy1 Providetheinfrastructure,governanceandresourcestosupportexistingandfuture

researchendeavours

2 FacilitateandsupportacultureofmedicalresearchwithintheGreenslopesPrivateHospitalthroughcompetitivescholarshipsandgrants

3 Communicateeffectively,therebyincreasingcommunityandcorporatesupportforthe

Foundationanditsresearch

4 ConsistentlydeliverexceptionalclinicalresearchactivitytoourpatientsandSponsors

5 Expansionwithinourspecialisationsandareasofexpertisetoincludeadditional

researchthemes.

Gallipoli M


nu

al Rep

ort 2012 – 2013

28


principal ActivitiesTheprincipalactivitiesofGallipoliMedicalResearchFoundationLtdduringthefinancialyearweretheestablishmentandundertakingofresearchprojects.

Nosignificantchangeinthenatureoftheseactivitiesoccurredduringtheyear.

How those activities assisted in achieving the company’s objectives

TheFoundationisdedicatedtoleadingthewayinchampioninglifechangingmedicalresearch.TheGallipoliMedicalResearchFoundation’sResearchCentresandClinicalTrialsUnitcontinuetostrivetirelesslytofindbetterwaystoprevent,treatandultimatelycurecurrentlyincurablediseases.

How the company measures its performance, including key performance indicators used by the company

TheFoundation’sResearchCommitteeassesstheresearchoutputsoftheresearchteamseachyear.EstablishedKeyPerformanceIndicatorsinclude:

• Numberofpublicationsbothquantityandqualitytakingintoconsiderationtheimpactfactorofjournals/rankingofthejournalinthefield

• Numberofstudentcompletions

• Abstractsandpresentationsquantityandquality

• Grantincomecomparedtomoneyraisedthroughcompetitivegrantroundsandquantityofthisincome

• Grantsubmissionsandreturnoninvestmentforresearchoutcomes

• Percentageofsciencecitation

• Hindex*–thesetofmostcitedpapersandthenumberofcitationsreceivedinotherpeople’spublications.

• Numberofpatientsinclinicaltrials/involvementinclinicaltrialsandpapersthereof.

WrittenreportsonresearchactivitiesareprovidedonceayearbytheteamsandpresentationsmadetotheResearchCommitteeandBoard.

(*TheHindexisanindexthatattemptstomeasureboththescientificproductivityandtheapparentscientificimpactofascientistorgroupofscientists.Theindexisbasedonthesetofthescientist’smostcitedpapersandthenumberofcitationsthattheyhavereceivedinotherpeople’spublications.)

Business reviewoperating Results

Thelossfromordinaryactivitiesafterprovidingforincometaxamountedto$322,698(2012:Profit$2,135,129).

Information on directorsprofessor John pearn Ao Qualifications AORFDMBBS(QLD)FRACS Experience SeniorpaediatricianattheRoyalChildren’sHospitalinBrisbane

Mr John Gallagher QC Qualifications BA,LLB Experience Barrister

Ms Carmel Monaghan Qualifications BusComm,MBA Experience NationalMarketingandPublicAffairsManager,RamsayHealthCareSpecialResponsibilities Secretary

Ms toni thornton (Absent for maternity leave during 2013) Qualifications BA,GradDip,AFIExperience ExecutiveDirectorofJBWere

Ms Jean pockett Experience FormerVicepresidentoftheWarWindowsGuild(QLD)Inc

Mr David McDonald Resigned 26 September 2012 Qualifications FIPA Experience FormerGeneralManagerof4BCand4BH

Dr Michael Harrison Qualifications MBBS(1stClassHonours),FRCPA(GeneralPathology) Experience ChiefExecutiveOfficer/ManagingPartneratSullivanNicolaides PathologyandConsultantPathologistinclinicalchemistry andmicrobiology

Directors’ Report continued

Gallipoli M


nu

al Rep

ort 2012 – 2013

29


Mr Stephen Copplin Appointed: 19 november 2012 Qualifications B.Bus(Acc)FCPA,FAICD

Experience ManagingDirectoroftheCFOCentrePtyLtd andAdjunctProfessorUniversityofQueenslandBusiness SchoolandITandElectricalEngineeringSchool

SpecialResponsibilities Chairman:FinanceandAuditSubCommittee ActingChairman:FundraisingSubCommittee

professor Keneth Donald Ao Appointed: 19 november 2012 Qualifications MBBS,PhD,FRCPA,FRCPath,FRACMA,FRACS(Hon) Experience ProfessorofAssessmentandEvaluationMedicalSchool GriffithUniversity

Dr peter Kortlucke Resigned 17 April 2013 Qualifications MBBS,FRACGP Experience Director,RehabilitationUnitGPH,Chairman,MedicalAdvisory CommitteeGPH(20062010),HeadofGeneralandGeriatric MedicineatGPHandHeadofStrokeUnitGreenslopes PrivateHospital

professor Ross Young Qualifications BSc(Hons),MSc,Dip,ClinPsyc,PhD,MAPS Experience ExecutiveDean,FacultyofHealthQueenslandUniversity ofTechnologySpecialResponsibilities ChairmanResearchandGovernanceSubCommittee

Dr David McMaugh Appointed: 17 April 2013 Qualifications MBA,MED,MDSc,BDSc,FRACDS Experience CEOandVinemasterBunjurgenEstateandformerClinical SpecialistandExecutiveLeaderwithinthehealthcarefield

professor nicholas Fisk Resigned 17 April 2013 Qualifications MBA,PhD,FRCOG,FRANZCOG,DDU,MBBSExperience ExecutiveDean,FacultyHealthSciences, UniversityofQueensland

Mark page Qualifications Bcom Experience CEOofGreenslopesPrivateHospital SpecialResponsibilities DeputyChairman

Associate professor David Colquhoun Qualifications MBBS,FRACP,FCSANZ Experience Consultantcardiologistinprivatepracticesince1984

Mr Cyril Gilbert oAM Experience WellknownQueenslander,highprofileadvocate andmentorfortheveterancommunity

Mr pat Welsh Experience SportsEditorChannel7News,Brisbane

Mr thomas Ryan Qualifications BPharm,FACP,FAICD Experience FormerDirectorandChairmanofAustralianPharmaceutical HealthCareSystems(APHS) SpecialResponsibilities Chairman


Gallipoli M


nu

al Rep

ort 2012 – 2013

30


Meetings of DirectorsDuringthefinancialyear,4BoardofDirector’smeetingsand6BoardSubcommiteemeetingswereheld.Attendancesbyeachdirectorduringtheyearwereasfollows:

Board Meetings Board Subcommittee Meetings

Numbereligibletoattend

Numberattended

Numbereligibletoattend

Numberattended

MrJohnGallagherQC 4 4 2 2

MrCyrilGilbertOAM 4 2 – –

DrMichaelHarrison 4 2 3 2

MrDavidMcDonald 1 1 1 1

MsCarmelMonaghan 4 3 – –

ProfessorJohnPearn 4 2 – –

MrsJeanPockett 4 4 – –

ProfessorKenethDonald 3 3 3 1

MrTomRyan 4 4 2 2

MrStephenCopplin 3 2 3 3

MsToniThornton* 4 – 1 –

MrPatWelsh 4 4 1 1

ProfessorRossYoung 4 3 3 3

ProfessorNickFisk 4 1 – –

AssociateProfessorDavidColquhoun

4 2 4 2

DrPeterKortlucke 3 3 – 2

MrMarkPage 4 3 1 1

DrDavidMcMaugh 1 – – –*MsToniThorntonwasonmaternityleaveduringtheyear.

other itemsSignificant Changes in State of Affairs

NosignificantchangesintheCompany’sstateofaffairsoccurredduringthefinancialyear.

After Balance Day events

NomattersorcircumstanceshavearisensincetheendofthefinancialyearwhichsignificantlyaffectedormaysignificantlyaffecttheoperationsoftheCompany,theresultsofthoseoperationsorthestateofaffairsoftheCompanyinfuturefinancialyears.

Auditors Independence Declaration

Acopyoftheauditor’sindependencedeclarationasrequiredundersection307CoftheCorporationsAct2001issetoutatpage8.

Indemnifying officers or Auditors

DirectorsandOfficersinsuranceamountingto$9824(2012$7088)waspaidduringtheyear.

proceedings on Behalf of Company

NopersonhasappliedforleaveofCourttobringproceedingsonbehalfoftheCompanyorinterveneinanyproceedingstowhichtheCompanyisapartyforthepurposeoftakingresponsibilityonbehalfoftheCompanyforalloranypartofthoseproceedings.

TheCompanywasnotapartytoanysuchproceedingsduringtheyear.

SignedinaccordancewitharesolutionoftheBoardofDirectors:

Director:

Mr thomas Ryan

Director:

Ms Carmel Monaghan

Dated this 25 day of September 2013


Gallipoli M


nu

al Rep

ort 2012 – 2013

31


Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

to the Board of Directors Gallipoli Medical Research Foundation ltd

Ideclarethat,tothebestofmyknowledgeandbelief,duringtheyearended30June2013,therehavebeen:

(i) nocontraventionsoftheauditorindependencerequirementsassetoutin theCorporationsAct2001inrelationtotheaudit;and

(ii) nocontraventionsofanyapplicablecodeofprofessionalconductinrelation

totheaudit.

Hanrick Curran Audit pty ltd Authorised Audit Company: 338599

Matthew Green

Director

Brisbane

Dated: 25 September 2013

Gallipoli M


nu

al Rep

ort 2012 – 2013

32


Statement of Profit or Loss and Other Comprehensive Income

note 2013 2012

$ $

Revenue 2 1,897,857 4,915,300Employeebenefitsexpense (919,921) (876,743)Depreciationandamortisationexpense (340,655) (176,336)Functionexpenses (13,326) (15,921)Researchexpenses (812,767) (844,570)ArtUnion – (667,733)Otherexpenses (133,886) (198,868)

Surplus/(deficit) before income tax (322,698) 2,135,129Incometaxexpense 1(d) – –

net surplus/(deficit) (322,698) 2,135,129

other comprehensive income/(loss) for the year, net of tax – –

total surplus/(deficit)for the year (322,698) 2,135,129

Theaccompanyingnotesformpartofthesefinancialstatements.

Gallipoli M


nu

al Rep

ort 2012 – 2013

33


note 2013 2012

$ $

ASSetSCURRENTASSETS Cashandcashequivalents 4 4,170,328 4,087,530Tradeandotherreceivables 5 110,898 223,855Otherassets 6 35,282 41,218

TOTALCURRENTASSETS 4,316,508 4,352,603

NONCURRENTASSETS Tradeandotherreceivables 5 – 4,500Property,plantandequipment 7 6,058,910 4,933,099Otherassets 180,000 210,000

TOTALNONCURRENTASSETS 6,238,910 5,147,599

TOTALASSETS 10,555,418 9,500,202

lIABIlItIeS CURRENTLIABILITIES Tradeandotherpayables 8 163,653 48,709Otherfinancialliabilities 9 1,541,651 250,000Employeebenefits 10 53,242 37,423

TOTALCURRENTLIABILITIES 1,758,546 336,132

NONCURRENTLIABILITIES Otherfinancialliabilities 9 110,000 154,500

TOTALNONCURRENTLIABILITIES 110,000 154,500

TOTALLIABILITIES 1,868,546 490,632

NETASSETS 8,686,872 9,009,570

eQuItY Retainedsurplus 8,686,872 9,009,570

TOTALEQUITY 8,686,872 9,009,570

Statement of Financial Position


Gallipoli M


nu

al Rep

ort 2012 – 2013

34


2013

Retained earnings total

$ $

Balanceat1July2012 9,009,570 9,009,570Deficit (322,698) (322,698)

Balanceat30June2013 8,686,872 8,686,872

2012

Retained earnings total

$ $

Balanceat1July2011 6,874,441 6,874,441Surplus 2,135,129 2,135,129

Balanceat30June2012 9,009,570 9,009,570

Statement of Changes in Equity


Gallipoli M


nu

al Rep

ort 2012 – 2013

35


Statement of Cash Flows note 2013 2012

$ $

CASH FRoM opeRAtInG ACtIVItIeS

Receiptsfromcustomers 2,339,669 1,509,645Paymentstosuppliersandemployees (1,661,615) (2,883,211)Donationsreceived 575,110 435,546Interestreceived 154,278 245,545Receiptsfromgrants 141,822 611,959Netcashprovidedby(usedin)operatingactivities 14(b) 1,549,264 (80,516)

CASH FloWS FRoM InVeStInG ACtIVItIeS

Paymentforproperty,plant&equipment (1,466,466) (2,097,483)Netcashusedbyinvestingactivities (1,466,466) (2,097,483)

CASH FloWS FRoM FInAnCInG ACtIVItIeS

Netincrease(decrease)incashandcashequivalentsheld 82,798 (2,177,999)Cashandcashequivalentsatbeginningofyear 4,087,530 6,265,529Cashandcashequivalentsatendoffinancialyear 14(a) 4,170,328 4,087,530


Gallipoli M


nu

al Rep

ort 2012 – 2013

36


Notes to the Financial Statements1 Statement of Significant Accounting PoliciesThefinancialreportisforGallipoliMedicalResearchFoundationLtdasanindividualentity,incorporatedanddomiciledinAustralia.GallipoliMedicalResearchFoundationLtdisaCompanylimitedbyguarantee.

Basis of preparationThefinancialstatementsareageneralpurposefinancialstatementsthathasbeenpreparedinaccordancewithAustralianAccountingStandardsReducedDisclosureRequirementsandtheCorporationsAct2001.ThecompanyisanotforprofitentityforfinanicalreportingpurposesunderAustralianAccountingStandards.

AustralianAccountingStandardssetoutaccountingpoliciesthattheAASBhasconcludedwouldresultinfinancialstatementscontainingrelevantandreliableinformationabouttransactions,eventsandconditions.Materialaccountingpoliciesadoptedinthepreparationofthesefinancialstatementsarepresentedbelowandhavebeenconsistentlyappliedunlessotherwisestated.

Thefinancialstatementshavebeenpreparedonanaccrualsbasisandarebasedonhistoricalcostsmodified,whereapplicable,bythemeasurementatfairvalueofselectednoncurrentassets,financialassetsandfinancialliabilities.

(a) Cash and Cash equivalentsCashandcashequivalentsincludecashonhand,depositsheldatcallwithbanks,othershorttermhighlyliquidinvestmentswithoriginalmaturitiesofthreemonthsorless,andbankoverdrafts.

(b) property, plant and equipmentEachclassofproperty,plantandequipmentiscarriedatcostorfairvalueless,whereapplicable,anyaccumulateddepreciationandimpairmentlosses.

Buildings

Buildingsaremeasuredonthecostbasislesssubsequentdepreciationforbuildings.

plant and equipment

Plantandequipmentaremeasuredonthecostbasislessdepreciationandimpairmentlosses.

Thecarryingamountofplantandequipmentisreviewedannuallybydirectorstoensureitisnotinexcessoftherecoverableamountfromtheseassets.Therecoverableamountisassessedonthebasisoftheexpectednetcashflowsthatwillbereceivedfromtheassets’employmentandsubsequentdisposal.Theexpectednetcashflowshavebeendiscountedtotheirpresentvaluesindeterminingrecoverableamounts.

Plantandequipmentthathavebeencontributedatnocost,orfornominalcost,arevaluedandrecognisedatthefairvalueoftheassetatthedateitisacquired.

Depreciation

Thedepreciableamountofallfixedassetsincludingbuildingsandcapitalisedleasedassets,butexcludingfreeholdland,isdepreciatedonadiminishingvaluebasisovertheasset’susefullifetotheCompanycommencingfromthetimetheassetisheldreadyforuse.Leaseholdimprovementsaredepreciatedovertheshorterofeithertheunexpiredperiodoftheleaseortheestimatedusefullivesoftheimprovements.

Thedepreciationratesusedforeachclassofdepreciableassetsare:Buildings 3% Furniture,FixturesandFittings 13% ComputerEquipment 24%

Theasset’sresidualvaluesandusefullivesarereviewed,andadjustedifappropriate,ateachbalancesheetdate.

Anasset’scarryingamountiswrittendownimmediatelytoitsrecoverableamountiftheasset’scarryingamountisgreaterthanitsestimatedrecoverableamount.

Gainsandlossesondisposalsaredeterminedbycomparingproceedswiththecarryingamount.Thesegainsandlossesareincludedintheincomestatement.Whenrevaluedassetsaresold,amountsincludedintherevaluationreserverelatingtothatassetaretransferredtoretainedearnings.

Gallipoli M


nu

al Rep

ort 2012 – 2013

37


(c) employee BenefitsProvisionismadefortheCompany’sliabilityforemployeebenefitsarisingfromservicesrenderedbyemployeestoBalanceSheetdate.Employeebenefitsarisingfromwages,salariesandannualleavearemeasuredatratesexpectedtobepaidwhentheliabilitiesaresettled.

(d) taxation StatusApprovalfromtheAustralianTaxationOfficewasgrantedon2July1996thattheincomeoftheFoundationisexemptfromthepaymentofincometaxundertheprovisionsofsection23(e)oftheIncomeTaxAssessmentAct1936.

(e) Goods and Services tax (GSt)Revenues,expensesandassetsarerecognisednetoftheamountofGST,exceptwheretheamountofGSTincurredisnotrecoverablefromtheTaxOffice.InthesecircumstancestheGSTisrecognisedaspartofthecostofacquisitionoftheassetoraspartofanitemoftheexpense.ReceivablesandpayablesinthestatementoffinancialpositionareshowninclusiveofGST.

Cashflowsarepresentedinthecashflowstatementonagrossbasis,exceptfortheGSTcomponentofinvestingandfinancingactivitieswhichisdisclosedasoperatingcashflows.

(f) RevenueRevenuefromthesaleofgoodsisrecogniseduponthedeliveryofgoodstocustomers.

Revenuefromdonationsandbequests,pledgesandgrantsarerecognisedasdescribedinNotes1(h)and1(i).

Interestrevenueisrecognisedusingtheeffectiveinterestratemethod,which,forfloatingratefinancialassets,istherateinherentintheinstrument.

Allrevenueisstatednetoftheamountofgoodsandservicestax(GST).

(g) unearned Income and pledges ReceivableFrequentlydonorscommittoprovideongoingsupportoveranumberofyearstotheFoundation.Thefullvalueoftheirpledgedamountisrecognisedasareceivableatthetimethepledgeismade.Amountsarenotrecognisedasrevenueuntilcashisreceived;thebalanceofanyoutstandingpledgeisrecognisedasunearnedincomeuntilcashisreceived.

(h) Grants ReceivedGrantsreceivedwithoutanyconditions,orunrelatedtospecificservices,arerecognisedasincomewhenreceived.Grantsreceivedontheconditionthatspecifiedservicesaredelivered,orconditionsfulfilled,areconsideredasreciprocalgrants.Suchreciprocalgrantsareinitiallyrecognisedasaliabilityandrevenueisrecognisedasservicesareperformedorconditionsarefulfilled.

(i) Research projects and GrantsAllresearchisexpensedwhenpaidandfuturecommitmentsaredisclosedbywayofnote.

(j) Contribution of Assets In KindWhereverpracticable,thefairvalueofanyassetsreceivedinkindbytheFoundationarerecognisedasincomewithacorrespondingrecognitionofanasset.

(k) Financial InstrumentsInitial Recognition and Measurement

Financialassetsandfinancialliabilitiesarerecognisedwhentheentitybecomesapartytothecontractualprovisionstotheinstrument.Forfinancialassets,thisistheequivalenttothedatethattheCompanycommitsitselftoeitherpurchaseorsaleoftheasset(ietradedateaccountingisadopted).

Financialinstrumentsareinitiallymeasuredatcostontradedate,whichincludestransactioncosts,whentherelatedcontractualrightsorobligationsexist.Subsequenttoinitialrecognitiontheseinstrumentsaremeasuredassetoutbelow.

Notes to the Financial Statements continued

Gallipoli M


nu

al Rep

ort 2012 – 2013

38


Classification and Subsequent Measurement

Financeinstrumentsaresubsequentlymeasuredateitheroffairvalue,amortisedcostusingtheeffectiveinterestratemethod,orcost.Fairvaluerepresentstheamountforwhichanassetcouldbeexchangedoraliabilitysettled,betweenknowledgeable,willingparties.Whereavailable,quotedpricesinanactivemarketareusedtodeterminefairvalue.Inothercircumstances,valuationtechniquesareadopted.

Amortised cost iscalculatedas:

• theamountinwhichthefinancialassetorfinancialliabilityismeasuredatinitialrecognition;

• lessprincipalrepayments;

• plusorminusthecumulativeamortisationofthedifference,ifany,betweentheamountinitiallyrecognisedandthematurityamountcalculatedusingtheeffective interest method;and

• lessanyreductionforimpairment.

Theeffective interest methodisusedtoallocateinterestincomeorinterestexpenseovertherelevantperiodandisequivalenttotheratethatexactlydiscountsestimatedfuturecashpaymentsorreceipts(includingfees,transactioncostsandotherpremiumsordiscounts)throughtheexpectedlife(orwhenthiscannotbereliablypredicted,thecontractualterm)ofthefinancialinstrumenttothenetcarryingamountofthefinancialassetorfinancialliability.Revisionstoexpectedfuturenetcashflowswillnecessitateanadjustmenttothecarryingvaluewithaconsequentialrecognitionofanincomeorexpenseinprofitorloss.

(i) loans and receivables

Loansandreceivablesarenonderivativefinancialassetswithfixedordeterminablepaymentsthatarenotquotedinanactivemarketandaresubsequentlymeasuredatamortisedcost.

(ii) Available for sale financial assets

Availableforsalefinancialassetsarenonderivativefinancialassetsthatareeithernotsuitabletobeclassifiedintoothercategoriesoffinancialassetsduetotheirnature,ortheyaredesignatedassuchbymanagement.Theycompriseinvestmentsintheequityofotherentitieswherethereisneitherafixedmaturitynorfixedordeterminablepayments.

(iii) Financial liabilities

Nonderivativefinancialliabilities(excludingfinancialguarantees)aresubsequentlymeasuredatamortisedcost.

Fair Value

Fairvalueisdeterminedbasedoncurrentbidpricesforallquotedinvestments.Valuationtechniquesareappliedtodeterminefairvalueforallunlistedsecurities,includingrecentarm’slengthtransactions,referencetosimilarinstrumentsandoptionpricingmodels.

Impairment

Ateachreportingdate,theCompanyassesseswhetherthereisobjectiveevidencethatafinancialinstrumenthasbeenimpaired.Inthecaseofavailableforsalefinancialinstruments,aprolongeddeclineinthevalueoftheinstrumentisconsideredtodeterminewhetheranimpairmenthasarisen.Impairmentlossesarerecognisedintheincomestatement.

Derecognition

Financialassetsarederecognisedwherethecontractualrightstoreceiptofcashflowsexpiresortheassetistransferredtoanotherpartywherebytheentitynolongerhasanysignificantcontinuinginvolvementintherisksandbenefitsassociatedwiththeasset.Financialliabilitiesarederecognisedwheretherelatedobligationsareeitherdischarged,cancelledorexpire.Thedifferencebetweenthecarryingvalueofthefinancialliabilityextinguishedortransferredtoanotherpartyandthefairvalueofconsiderationpaid,includingthetransferofnoncashassetsorliabilitiesassumedisrecognisedinprofitorloss.


Gallipoli M


nu

al Rep

ort 2012 – 2013

39


(l) Adoption of new and Revised Accounting StandardsDuringthecurrentyeartheCompanyadoptedallofthenewandrevisedAustralianAccountingStandardsandInterpretationsapplicabletoitsoperationswhichbecamemandatory.

TheCompanyearlyadoptedAASB1053ApplicationofTiersofAustralianAccountingStandardsandAASB20102AmendmentstoAustralianAccountingStandardsarisingfromReducedDisclosureRequirementsforthefinancialyearbeginningon1July2010toprepareTier2generalpurposefinancialstatements.

TheCompanyalsoearlyadoptedAASB20112AmendmentstoAustralianAccountingStandardsarisingfromtheTransTasmanConvergenceProject–ReducedDisclosureRequirementsforthefinancialyearbeginning1July2011.

(m) new Accounting Standards for Application in Future periodsOtherthanasdisclosedabove,theAASBhasissuednewandamendedaccountingstandardsandinterpretationsthathavemandatoryapplicationdatesforfuturereportingperiods.Thecompanyhasdecidedagainstearlyadoptionofthesestandards

Theapplicationofthosestandardswhichwillapplytothecompanyhavebeenreviewedandithasbeenassessedthattheywillnothaveanymaterialimpacttothecompany’sfinancialreport.


Gallipoli M


nu

al Rep

ort 2012 – 2013

40


2013 2012

$ $

2 Revenueoperating activities

Grants 141,822 2,545,984Artunionincome – 856,448Clinicaltrialincome 781,456 606,065Donations 575,110 435,546Interestreceived 154,278 245,545Bequestincome 105,741 76,583Fundraisingincome 13,777 7,400Otherrevenue 125,673 141,729

TotalRevenue 1,897,857 4,915,300

3 Result for the Year(a) expenses Depreciationbuildings 340,655 176,336 Researchexpenses 812,767 844,570 Employeebenefitsexpense 919,921 876,743

4 Cash and Cash EquivalentsCashonhand 200 200Cashatbank 1,642,316 3,087,330Shorttermbankdeposits 2,527,812 1,000,000

4,170,328 4,087,530


Gallipoli M


nu

al Rep

ort 2012 – 2013

41


2013 2012

$ $

5 Trade and Other ReceivablesCuRRent

Tradereceivables 33,871 99,742Deposits 45,931 41,047GSTreceivable 31,096 45,566Pledgereceivables – 37,500

Totalcurrenttradeandotherreceivables 110,898 223,855

non CuRRent

Pledgereceivables – 4,500

Totalnoncurrenttradeandotherreceivables – 4,500

6 Other AssetsCuRRent

Prepayments 34,279 38,659Accruedrevenue 1,003 2,559

35,282 41,218

non CuRRent

Prepayments 180,000 210,000


Gallipoli M


nu

al Rep

ort 2012 – 2013

42


2013 2012

$ $

7 Property Plant and EquipmentBuIlDInGSAtcost 3,412,430 1,156,880Accumulateddepreciation (238,151) (181,799)

Totalbuildings 3,174,279 975,081

plAnt AnD eQuIpMent Capital works in progress Atcost – 2,676,679Totalcapitalworksinprogress – 2,676,679

Furniture, fixture and fittings Atcost 3,374,346 1,604,481Accumulateddepreciation (666,812) (414,249)Totalfurniture,fixtureandfittings 2,707,534 1,190,232

Computer equipment Atcost 240,681 122,950Accumulateddepreciation (81,902) (50,161)Totalcomputerequipment 158,779 72,789

Artwork Atcost 18,318 18,318TotalArtwork 18,318 18,318

Totalplantandequipment 2,884,631 3,958,018

total property, plant and equipment 6,058,910 4,933,099


Gallipoli M


nu

al Rep

ort 2012 – 2013

43


(a) Movements in Carrying Amounts

Movementinthecarryingamountsforeachclassofproperty,plantandequipmentbetweenthebeginningandtheendofthecurrentfinancialyear:

Furniture, Capital works Fixtures & Computer in business Buildings Fittings equipment Artwork total

$ $ $ $ $ $

Balance at 30 June 2013

Balanceat1July2012 2,676,679 975,081 1,190,232 72,789 18,318 4,933,099Additions 190,381 – 1,158,355 117,730 – 1,466,466Transferredfromcapitalworksinprogress (2,867,060) 2,255,550 611,510 – – –Depreciationexpense – (56,352) (252,563) (31,740) – (340,655)

Balanceat30June2013 – 3,174,279 2,707,534 158,779 18,318 6,058,910

Balance at 30 June 2012

Balanceat1July2011 1,334,843 1,005,238 630,756 39,887 1,227 3,011,951Additions 1,341,836 – 685,665 52,892 17,091 2,097,484Depreciationexpense – (30,157) (126,189) (19,990) – (176,336)

Balanceat30June2012 2,676,679 975,081 1,190,232 72,789 18,318 4,933,099


Gallipoli M


nu

al Rep

ort 2012 – 2013

44


2013 2012

$ $

8 Trade and Other PayablesCuRRent unsecured liabilities

Tradepayables 136,552 21,817Otherpayables 27,101 26,892

163,653 48,709

9 Other LiabilitiesCuRRent

Unearnedincome 1,541,651 250,000

1,541,651 250,000

non CuRRent

Unearnedincome 110,000 154,500

110,000 154,500


Gallipoli M


nu

al Rep

ort 2012 – 2013

45


2013 2012

$ $

10 Employee BenefitsCuRRent

Provisionforannualleave 53,242 37,423

11 Key Management Personnel DisclosuresThetotalremunerationpaidtokeymanagementpersonneloftheCompanyis$284,334(2012:$$276,657).

Thecompanyhasalsorecordedliabilitestokeymanagementpersonnelassociatedwithemployeebenefitsrelatingtoaccruedsalaryandwages,annualleaveandlongserviceleave.Theseamountsariseinaccordancewithemploymentagreementsandapplicableemploymentlegislation.

12 Related Party TransactionsOtherthantransactionswithkeymanagementpersonneldescribedabove,therewerenootherrelatedpartytransactionsthatoccurredduringthefinancialyear.

13 Members’ GuaranteeTheCompanyisincorporatedundertheCorporationsAct2001andisaCompanylimitedbyguarantee.IftheCompanyiswoundup,theConstitutionstatesthateachmemberisrequiredtocontributeamaximumof$10eachtowardsmeetinganyoutstandingsandobligationsoftheCompany.At30June2013thenumberofmemberswas15(2012:15).


Gallipoli M


nu

al Rep

ort 2012 – 2013

46


2013 2012

$ $

14 Cash Flow Information(a) Reconciliation of cash

Cashattheendofthefinancialyearasshowninthestatementofcashflowsisreconciledtoitemsinthestatementoffinancialpositionasfollows:

Cashandcashequivalents 4,170,328 4,087,530

4,170,328 4,087,530 (b) Reconciliation of result for the year to cashflows from operating activities

Reconciliationofnetincometonetcashprovidedbyoperatingactivities:

Profitfortheyear (322,698) 2,135,129Noncashflowsinprofit: Depreciation 340,655 176,336Changesinassetsandliabilities: (Increase)/Decreaseintradereceivables 65,871 (10,924)(Increase)/Decreaseinprepayments 87,522 61,819Increase/(Decrease)intradepayables 114,735 (20,272)Increase/(Decrease)inothertradepayablesandaccruals 16,028 (226,880)Increase/(Decrease)inunearnedincome 1,247,151 (261,697)Increase/(Decrease)inGallipoliResearchBuildingFund – (1,934,027)

Cashflowfromoperations 1,549,264 (80,516)


Gallipoli M


nu

al Rep

ort 2012 – 2013

47


2013 2012

$ $

15 Capital and Leasing Commitment and Contingencies(a) operating lease Contingencies

ThecompanyhasanoncancellableoperatingleasewithRamsayHospitalHoldings(Queensland)PtyLtdforaperiodof10yearscommencingfrom15November2006.Thecompanyisentitledtoarentabatementequivalenttothefullvalueoftherentprovidingthetermsoftheleasearecompliedwith.

Whilethetermsoftheleasearecompliedwiththerearenoamountspayable.However,ifthetermsoftheleasewerenotcompliedwith,thefollowingamountswillbepayable.

Payableminimumleasepayments –notlaterthan12months 13,250 113,250–between12monthsand5years 264,250 377,500

377,500 490,750

(b) Capital expenditure Commitments

ConstructionoftheGallipoliResearchCentrehasbeencompletedduringtheyearandtheentityhasnotcommittedtoanyfurthercapitalexpenditureasat30June2013.

16 Events After the End of the Reporting PeriodThefinancialreportwasauthorisedforissueon25thSeptember2013bytheboardofdirectors.

15 Company Detailsthe registered office of the company is:

GreenslopesPrivateHospitalNewdegateStreetGREENSLOPESQLD4120


Gallipoli M


nu

al Rep

ort 2012 – 2013

48


Directors’ DeclarationThedirectorsoftheCompanydeclarethat:

1.Thefinancialstatementsandnotes,assetoutonpages9to24,areinaccordance withtheCorporations Act 2001and:

a. complywithAccountingStandardsReducedDisclosureRequirement;and

b.giveatrueandfairviewofthefinancialpositionasat30June2013andofthe performancefortheyearendedonthatdateoftheCompany.

2.Inthedirectors’opinion,therearereasonablegroundstobelievethattheCompany willbeabletopayitsdebtsasandwhentheybecomedueandpayable.

ThisdeclarationismadeinaccordancewitharesolutionoftheBoardofDirectors.

Director:

Mr thomas Ryan

Director:

Ms Carmel Monaghan

Dated this 25 day of September 2013

Gallipoli M


nu

al Rep

ort 2012 – 2013

49


Independent Audit Report to the members of Gallipoli Medical Research Foundation Ltd

Report on the Financial ReportWehaveauditedtheaccompanyingfinancialreportofGallipoliMedicalResearchFoundationLtd,whichcomprisesthestatementoffinancialpositionasat30June2013,thestatementofcomprehensiveincome,statementofchangesinequityandstatementofcashflowsfortheyearthenended,notescomprisingasummaryofsignificantaccountingpoliciesandotherexplanatoryinformation,andthedirectors’declaration.

Directors’ Responsibility for the Financial Report ThedirectorsoftheCompanyareresponsibleforthepreparationofthefinancialreportthatgivesatrueandfairviewinaccordancewithAustralianAccountingStandardsandtheCorporationsAct2001andforsuchinternalcontrolasthedirectorsdetermineisnecessarytoenablethepreparationofthefinancialreportthatisfreefrommaterialmisstatement,whetherduetofraudorerror.

Auditor’s Responsibility Ourresponsibilityistoexpressanopiniononthefinancialreportbasedonouraudit.WeconductedourauditinaccordancewithAustralianAuditingStandards.Thosestandardsrequirethatwecomplywithrelevantethicalrequirementsrelatingtoauditengagementsandplanandperformtheaudittoobtainreasonableassuranceaboutwhetherthefinancialreportisfreefrommaterialmisstatement.

Anauditinvolvesperformingprocedurestoobtainauditevidenceabouttheamountsanddisclosuresinthefinancialreport.Theproceduresselecteddependontheauditor’sjudgement,includingtheassessmentoftherisksofmaterialmisstatementofthefinancialreport,whetherduetofraudorerror.Inmakingthoseriskassessments,theauditorconsidersinternalcontrolrelevanttotheentity’spreparationofthefinancialreportthatgivesatrueandfairviewinordertodesignauditproceduresthatareappropriateinthecircumstances,butnotforthepurposeofexpressinganopinionontheeffectivenessoftheentity’sinternalcontrol.Anauditalsoincludesevaluatingtheappropriatenessofaccountingpoliciesusedandthereasonablenessofaccountingestimatesmadebythedirectors,aswellasevaluatingtheoverallpresentationofthefinancialreport.

Webelievethattheauditevidencewehaveobtainedissufficientandappropriatetoprovideabasisforourauditopinion.

IndependenceInconductingouraudit,wehavecompliedwiththeindependencerequirementsoftheCorporationsAct2001.WeconfirmthattheindependencedeclarationrequiredbytheCorporationsAct2001,whichhasbeengiventothedirectorsofGallipoliMedicalResearchFoundationLtd,wouldbeinthesametermsifgiventothedirectorsasatthetimeofthisauditor’sreport.

OpinionInouropinionthefinancialreportofGallipoliMedicalResearchFoundationLtdisinaccordancewiththeCorporations Act 2001,including:

(a)givingatrueandfairviewoftheCompany’sfinancialpositionasat30June2013andofitsperformancefortheyearendedonthatdate;and

(b)complyingwithAustralianAccountingStandardsandtheCorporations Regulations 2001.

Hanrick Curran Audit pty ltd

AuthorisedAuditCompany:338599

MatthewGreen

Director

Brisbane

Dated: 25 September 2013

Gallipoli M


nu

al Rep

ort 2012 – 2013

50

TheGallipoliMedicalResearchFoundation(GMRF)isdedicatedtoleadingthewayinchampioninglifechangingmedicalresearch.Thankssimplytoongoingfinancialsupportfrompeoplelikeyou,itsworldrenownedresearchteamsstrivetirelesslytofindbetterwaystoprevent,treatandultimatelycurecurrentlyincurabledisease.

ReceivingnoregulargovernmentfundingtheFoundationreliesondonationsfromthecommunitytocontinueitsvitalresearch.Everygift,howeverbigorsmallwillmakeadifferenceandhelpsavelives–thankyou.

BequestsFormanypeopleleavingabequestintheirWillisoneofthemostsignificantwaystheycanassistacharityandleavealastinglegacy.Afterconsideringfamilyandfriends,ifyouwouldliketomakeprovisioninyourWilltoassisttheGMRF,youcanmakeyourbequestdirectlytotheFoundationbyvisitingyourownsolicitor.

Suggested wording to use when making your bequest:

pecuniary (a specific amount)

I give devise and bequeath, free of all duties and charges, the sum of […write in words and numbers…] to the GAllIpolI MeDICAl ReSeARCH FounDAtIon ltD, ACn 077 750 693, for the purposes of conducting research at Greenslopes Private Hospital or in such manner as the Board of the Gallipoli Medical Research Foundation may determine. And I direct that the receipt of the Secretary of the Gallipoli Medical Research Foundation shall be a full and sufficient discharge to my Executor for the bequest, which is to be applied to the general purposes of the Foundation.

Residuary (a percentage share of an estate)

I give devise and bequeath, free of all duties and charges, a [……insert quantum of share (e.g. one half share) or a percentage ….] of my residuary estate to the GAllIpolI MeDICAl ReSeARCH FounDAtIon ltD, ACn 077 750 693, for the purposes of conducting research at Greenslopes Private Hospital, or in such manner as the Board of the Gallipoli Medical Research Foundation may determine. And I direct that the receipt of the Secretary of the Gallipoli Medical Research Foundation shall be a full and sufficient discharge to my Executor for the bequest, which is to be applied to the general purposes of the Foundation.

IfyouwouldlikeafreecopyofourbequestbrochureoradviceaboutmakingorupdatingyourWillpleasecontacttheFoundationOffice.

Community FundraisingTheFoundationreliesontheamazingeffortsofmanyindividualsandcommunitygroupstoraisefundsintheirlocalcommunity.IfyouoryourcommunitygroupwouldbeinterestedinfindingoutmoreabouthowtodothispleasecontacttheFoundationOfficeforfurtherinformation.

DonationsReceivingnoregulargovernmentfundingtheFoundationreliesondonationsandfund-raisingactivities–donationscanbemadebycheque,creditcardoronline.

Gallipoli Medical Research Foundation, Greenslopes Private Hospital Newdegate Street GREENSLOPES QLD 4120

T: (07) 3394 7284

W: www.gallipoliresearch.com.au

TomakearegularorsignificantgiftorifyouwouldlikefurtherinformationaboutjoiningthePreciousMetalsCircleorCyrilGilbertTestimonialFundpleasecontacttheFoundationOffice.All donations of $2 or more are tax deductible – thank you.

Memorial GiftsMemorialdonationscanbemadetotheGMRFinlieuoffloraltributes.MemorialgiftenvelopesareavailablefromtheFoundationOffice,ortheycanberequestedviayourfuneraldirector.

tributeTributeisthenewsletteroftheGMRFandproducedtwiceayear.IfyouwouldliketoreceiveacopypleasecontacttheFoundationOffice.

VolunteeringTheDiggersDozenvolunteersbasedatGreenslopesPrivateHospitalarealwaysonthelookoutfornewvolunteers.IfyoucanhelppleasecontactPresidentJoanHarrison(07)3394 7026.

Foundation office contact details:Gallipoli Medical Research Foundation

GreenslopesPrivateHospitalNewdegateStreet,GREENSLOPESQLD4120

T:(07)3394 7284Fax:(07)33947767E:[email protected]:www.gallipoliresearch.com.au

ABN 42 077 750 693

How you can help

Gallipoli M


nu

al Rep

ort 2012 – 2013

51

TheGallipoliMedicalResearchFoundationlogoincludesarepresentationofSimpsonandhisdonkey,awellknownandmuchlovediconthatepitomisesthesacrificemadebyourbraveservicepersonnelatGallipoliandinmanyconflictssincethattragicbutheroicchapterinourhistory.Thecommitment,dedicationandselflessnessthatenabledSimpsontogoout,timeandagain,torescuehiswoundedcomradesencouragesustostrivetowardsexcellenceinmedicalresearchsothatotherscanbenefitinthisgenerationandgenerationstocome.

JohnSimpsonKirkpatrickwasbornandliveduntilagesixteeninSouthShields,Tyneside,UK.Oneofafamilyofsevenincludinghisfather,Robert,amerchantnavyseamanandSarah,hismotherwhoalsoworkedasadomestichousekeeper,John’syounglifewasdifficult.Foodwasscarce,theneighbourhoodwaspoorandthefamilymovedfrequently.Hisfatherpassedaway,fiveyearsafterheleftthenavybecauseofinjury.Johnwas17.Hehadleftschoolat12totakeupworkasa“milk-floatboy”.Heworkedwithadappledgreyponywhobecamehisclosefriend;othersremarkingonthefactthatJohntalkedtotheponylikehewouldanotherhumanbeing.

Whenhisfatherdied,JohnwenttoseaandonhissecondshiphecametoAustralia.Heworkedhereforfouryears,oncoastalshippingvesselsandhetriedcanecuttingandhorse-mountedstockworkinNorthernQueensland.Theselatterjobseachlastedonlyamatterofdays;Johnfoundtheheatandhumidityintolerable.Whenwarbrokeoutin1914,hewasoneofthefirsttoenlistinPerthwherehejoinedthe3AustralianFieldAmbulanceasastretcherbearer.

ThelegendofSimpson’sdeedsatGallipoliwasforgedinonly24daysatAnzacCove.Itisbelievedthatherescuedandretrievedmorethan300casualties,sometimesasmanyas20inoneday,manyunderconditionsofmortalrisktohimself.On19May1915,whilemakinghisfourthrescueofthedayunderheavyfire,hewaskilledinstantlybymachinegunfireatapointknownasBloodyAngelinShrapnelGully.Hisdonkey,“Duffy”stillcarryingthewoundedsoldierreturnedalonetotheAdvancedDressingStationof3FieldAmbulance.

Acknowledgement: professor John pearn Ao, professor of paediatrics and Child Health – university of Queensland and Major General (Rtd.)

Gallipoli Medical Research Foundation GreenslopesPrivateHospitalNewdegateStreetGREENSLOPESQLD4120

T:(07)3394 7284 Fax:(07)33947767E:[email protected]:www.gallipoliresearch.com.auABN 42 077 750 693

2012/13 - gallipoli – enhancing health through the ... · 2012. terry’s phd focused on liver...

Documents